

Contents

Company information

Breakdown of capital	1
----------------------	---

Individual financial statements

Balance sheet - Assets	2
------------------------	---

Balance sheet - Liabilities	4
-----------------------------	---

Statement of income	6
---------------------	---

Statement of comprehensive income	7
-----------------------------------	---

Statement of cash flows (Indirect method)	8
---	---

Statement of changes in shareholders' equity

Statement of changes in shareholders' equity (DMPL) – 01/01/2024–03/31/2024	9
---	---

Statement of changes in shareholders' equity (DMPL) – 01/01/2023–03/31/2023	10
---	----

Statement of added value	11
--------------------------	----

Consolidated financial statements

Balance sheet - Assets	12
------------------------	----

Balance sheet - Liabilities	14
-----------------------------	----

Statement of income	16
---------------------	----

Statement of comprehensive income	18
-----------------------------------	----

Statement of cash flows (Indirect method)	19
---	----

Statement of changes in shareholders' equity

Statement of changes in shareholders' equity (DMPL) – 01/01/2024–03/31/2024	20
---	----

Statement of changes in shareholders' equity (DMPL) – 01/01/2023–03/31/2023	21
---	----

Statement of added value	22
--------------------------	----

Performance comment	23
---------------------	----

Notes to the financial statements	51
-----------------------------------	----

Other information the Company deems to be relevant	72
--	----

Opinions and Statements

Special review report - Unqualified	75
-------------------------------------	----

Statement of the Executive Officers on the Financial Statements	76
---	----

Statement of the Directors on Independent Auditor's Report	77
--	----

Company information / Breakdown of capital

Quantity of shares (Unit)	Current quarter 03/31/2024
Paid-in capital	
Common	552,495,663
Preferred	0
Total	552,495,663
Treasury	
Common	1,854,600
Preferred	0
Total	1,854,600

Individual financial statements / Balance sheet – Assets
(In thousand of reais)

Code of account	Account description	Current quarter 03/31/2024	Prior year 12/31/2023
1	Total assets	2,275,911	2,113,074
1.01	Current assets	578,884	451,215
1.01.01	Cash and cash equivalents	11,956	13,615
1.01.02	Interest earning bank deposits	496,812	329,646
1.01.02.01	Interest earning bank deposits measured at fair value through profit or loss	347,892	180,916
1.01.02.01.04	Free investments	347,892	180,916
1.01.02.03	Interest earning bank deposits measured at amortized cost	148,920	148,730
1.01.02.03.01	Investments that guarantee technical reserves	19,949	20,060
1.01.02.03.02	Free investments	128,971	128,670
1.01.03	Accounts receivable	60,295	98,921
1.01.03.01	Clients	38,097	31,125
1.01.03.01.06	Assets of insurance and reinsurance contracts	38,097	31,125
1.01.03.02	Other accounts receivable	22,198	67,796
1.01.03.02.01	Advances to suppliers and others	40	127
1.01.03.02.02	Advances to employees	8,932	9,095
1.01.03.02.03	Other Credits Receivable	13,226	58,574
1.01.06	Recoverable taxes	7,318	4,794
1.01.06.01	Current recoverable taxes	7,318	4,794
1.01.06.01.01	Tax and social security credits	7,318	4,794
1.01.07	Prepaid expenses	2,503	4,239
1.01.07.20	Other	2,503	4,239
1.02	Non-current assets	1,697,027	1,661,859
1.02.01	Non-current receivables	729,237	696,933
1.02.01.03	Interest earning bank deposits measured at amortized cost	641,658	620,125
1.02.01.03.01	Investments that guarantee technical reserves	173,094	173,839
1.02.01.03.03	Free investments	468,564	446,286
1.02.01.07	Deferred taxes	17,912	8,762
1.02.01.07.01	Deferred income tax and social contribution	17,912	8,762
1.02.01.10	Other non-current assets	69,667	68,046
1.02.01.10.03	Judicial and tax deposits	30,297	29,203
1.02.01.10.04	Other credits receivable	14,885	14,885
1.02.01.10.06	Tax and social security credits (recoverable taxes)	24,485	23,958
1.02.02	Investments	82,283	80,550
1.02.02.01	Equity interest	82,283	80,550
1.02.02.01.02	Interest in subsidiaries	78,423	76,082
1.02.02.01.03	Joint ownership	3,860	4,468
1.02.03	Property, plant and equipment	25,971	27,633
1.02.03.01	Construction in progress	14,059	15,261
1.02.03.01.01	Property, plant and equipment for use	9,986	10,899
1.02.03.01.02	Other fixed assets	4,073	4,362
1.02.03.02	Right-of-use in lease	11,912	12,372
1.02.03.02.01	Right-of-use (CPC 06 (R2)/IFRS 16)	11,912	12,372
1.02.04	Intangible assets	859,536	856,743
1.02.04.01	Intangible assets	859,536	856,743

Individual financial statements / Balance sheet – Assets
(In thousand of reais)

Code of account	Account description	Current quarter 03/31/2024	Prior year 12/31/2023
1.02.04.01.02	Goodwill on acquisition of investments	654,948	654,948
1.02.04.01.03	Development of systems, software use licenses	182,618	178,067
1.02.04.01.05	Allocated intangible assets	21,970	23,728

Individual financial statements / Balance sheet – Assets
(In thousand of reais)

Code of account	Account description	Current quarter 03/31/2024	Prior year 12/31/2023
2	Total liabilities	2,275,911	2,113,074
2.01	Current liabilities	672,158	614,528
2.01.01	Social and labor obligations	64,820	58,250
2.01.01.01	Social charges	6,403	6,465
2.01.01.01.01	Charges payable	6,403	6,465
2.01.01.02	Labor obligations	58,417	51,785
2.01.01.02.01	Salaries, vacation and fees	58,417	51,785
2.01.02	Suppliers	17,284	20,292
2.01.02.01	Domestic suppliers	17,284	20,292
2.01.02.01.01	Trading on operations	4,625	7,094
2.01.02.01.02	Suppliers of goods and services	10,718	11,388
2.01.02.01.04	Consideration/premiums to be repaid	135	53
2.01.02.01.05	Lease liabilities (CPC 06 (R2)/IFRS 16)	2,735	2,716
2.01.02.01.06	Adjustment to present value - lease liabilities (CPC 06 (R2)/IFRS 16)	-929	-959
2.01.03	Tax liabilities	36,166	20,957
2.01.03.01	Federal tax liabilities	33,257	17,824
2.01.03.01.01	Income tax and social contribution payable	20,416	4,344
2.01.03.01.02	Other federal tax liabilities	12,841	13,480
2.01.03.03	Municipal tax liabilities	2,909	3,133
2.01.05	Other liabilities	260,270	239,105
2.01.05.02	Other	260,270	239,105
2.01.05.02.01	Dividends and interest on own capital	19,425	16,731
2.01.05.02.02	Minimum mandatory dividend payable	184,761	184,761
2.01.05.02.04	Advances from clients	583	601
2.01.05.02.05	Other accounts payable	28,140	31,930
2.01.05.02.06	Repurchase of shares payable	22,185	0
2.01.05.02.08	Investments payable	5,176	5,082
2.01.06	Provisions	293,618	275,924
2.01.06.02	Other provisions	293,618	275,924
2.01.06.02.09	Liabilities of insurance and reinsurance contracts	293,618	275,924
2.02	Non-current liabilities	119,106	111,552
2.02.02	Other liabilities	56,322	51,802
2.02.02.02	Other	56,322	51,802
2.02.02.02.03	Other liabilities	16,183	16,063
2.02.02.02.04	Fees payable	0	97
2.02.02.02.06	Investments payable	3,563	3,563
2.02.02.02.07	Lease liabilities (CPC 06 (R2)/IFRS 16)	15,611	16,304
2.02.02.02.08	Adjustment to present value - lease liabilities (CPC 06 (R2)/IFRS 16)	-2,734	-2,954
2.02.02.02.09	Long-term incentive (ILP)	23,699	18,729
2.02.04	Provisions	62,784	59,750
2.02.04.01	Tax, social security, labor and civil provision	36,069	33,884
2.02.04.01.01	Tax provision	616	598
2.02.04.01.02	Social security and labor provisions	1,179	1,231
2.02.04.01.04	Civil provision	34,274	32,055

Individual financial statements / Balance sheet – Assets
(In thousand of reais)

Code of account	Account description	Current quarter 03/31/2024	Prior year 12/31/2023
2.02.04.02	Other provisions	26,715	25,866
2.02.04.02.05	Taxes and charges payable	26,715	25,866
2.03	Shareholders' equity	1,484,647	1,386,994
2.03.01	Realized capital	851,017	851,017
2.03.02	Capital reserves	-35,610	-35,610
2.03.02.10	Goodwill/negative goodwill in capital transaction	-35,610	-35,610
2.03.04	Profit reserves	539,500	561,679
2.03.04.01	Legal reserve	100,749	100,749
2.03.04.07	Tax incentive reserve	129	129
2.03.04.08	Additional dividend proposed	242,492	242,492
2.03.04.09	Treasury shares	-22,179	0
2.03.04.10	Statutory Reserve of Regulatory Capital	100,000	100,000
2.03.04.11	Investment and expansion reserve	60,373	60,373
2.03.04.12	First Investment Reserve	57,936	57,936
2.03.05	Retained earnings/losses	123,958	0
2.03.06	Equity valuation adjustments	-793	-800
2.03.07	Accumulated translation adjustments	2,580	2,009
2.03.08	Other comprehensive income	3,995	8,699

Individual financial statements / Statement of income
(In thousand of reais)

Code of account	Account description	Accumulated of the current year 01/01/2024–03/31/2024	Accumulated of the prior year 01/01/2023–03/31/2023
3.01	Revenue from sales of goods and/or services	531,106	491,127
3.01.07	Insurance revenue (PAA)	409,733	385,250
3.01.08	Insurance revenue (BBA)	121,373	105,877
3.02	Cost of goods and/or services sold	-347,007	-324,088
3.02.08	Insurance costs	-347,007	-324,088
3.03	Gross income	184,099	167,039
3.04	Operating expenses/revenue	615	7,821
3.04.02	General and administrative expenses	-12,410	-9,874
3.04.02.01	Administrative expenses	-12,131	-9,874
3.04.02.05	Income (loss) from disposal or write-off of non-current asset items and other	-279	0
3.04.04	Other operating revenue	12,547	18,333
3.04.04.01	Other operating revenues from Health care plans	12,428	18,230
3.04.04.02	Revenues from health care plans for the Operator	119	103
3.04.05	Other operating expenses	-5,370	-5,548
3.04.05.02	Provision for credit losses	141	39
3.04.05.03	Profit sharing	-5,511	-5,587
3.04.06	Equity in net income of subsidiaries	5,848	4,910
3.05	Income (loss) before financial income and taxes	184,714	174,860
3.06	Financial income (loss)	23,494	23,705
3.06.01	Financial revenues	35,378	26,320
3.06.01.01	Financial revenues	35,378	26,320
3.06.02	Financial expenses	-11,884	-2,615
3.06.02.01	Financial expenses	-11,633	-2,347
3.06.02.02	Adjustment to present value - lease liabilities (CPC 06 (R2)/IFRS 16)	-251	-268
3.07	Income (loss) before income tax	208,208	198,565
3.08	Income tax and social contribution	-61,471	-58,843
3.08.01	Current	-68,234	-71,489
3.08.02	Deferred	6,763	12,646
3.09	Net income (loss) from continued operations	146,737	139,722
3.11	Income/loss for the period	146,737	139,722
3.99	Earnings per share - (Reais R\$ / Shares)		
3.99.01	Basic earnings per share		
3.99.01.01	COMMON SHARES	0.26559	0.25289
3.99.02	Diluted earnings per share		
3.99.02.01	COMMON SHARES	0.26559	0.25289

Individual financial statements / Statement of comprehensive income**(In thousand of reais)**

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2024–03/31/2024	01/01/2023–03/31/2023
4.01	Net income for the period	146,737	139,722
4.02	Other comprehensive income	5,782	-53,726
4.02.01	Accumulated translation adjustment	2,580	2,009
4.02.03	Other comprehensive income of investees recognized under the equity method	54	-485
4.02.04	Other comprehensive income	3,941	-54,450
4.02.05	Equity valuation adjustments of investees recognized under the equity method	-793	-800
4.03	Comprehensive income for the period	152,519	85,996

Individual financial statements / Statement of changes in shareholders' equity / DMPL – 01/01/2024–03/31/2024

(In thousand of reais)

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2024–03/31/2024	01/01/2023–03/31/2023
6.01	Net cash from operational activities	48,481	138,746
6.01.01	Cash generated in operations	211,739	211,355
6.01.01.01	Net income (loss) for the period	146,737	139,722
6.01.01.02	Depreciation and amortization	11,591	9,360
6.01.01.03	Net inflation adjustments	-2,848	10,288
6.01.01.05	Provision for lawsuits (Contingencies)	460	-2,052
6.01.01.06	Income (loss) from disposal of non-current assets and other	279	0
6.01.01.07	Equity in net income of subsidiaries	-5,848	-4,910
6.01.01.08	Provision for credit losses	-141	-39
6.01.01.11	Provision for income tax and social contribution	61,471	58,843
6.01.01.13	Amortization of Right-of-use (CPC 6 (R2)/IFRS 16)	460	447
6.01.01.14	Rents (CPC 06 (R2)/IFRS 16)	-673	-572
6.01.01.15	Adjustment to present value - lease liabilities (CPC 06 (R2)/IFRS 16)	251	268
6.01.02	Changes in assets and liabilities	-163,258	-72,609
6.01.02.01	Interest earning bank deposits (Financial assets at fair value through profit or loss)	-166,976	-16,050
6.01.02.03	Other accounts receivable, recoverable taxes and prepaid expenses	44,810	506
6.01.02.05	Non-current receivables	2,578	-747
6.01.02.06	Assets and liabilities of insurance and reinsurance contracts	3,841	46,635
6.01.02.09	Tax obligations (taxes payable)	-863	-2,133
6.01.02.10	Labor obligations, Suppliers, Advance from clients and Other accounts payable (Sundry debits)	1,630	-24,714
6.01.02.11	Non-current liabilities	6,416	-4,918
6.01.02.13	Income tax and social contribution paid	-52,163	-69,870
6.01.02.14	Social charges (Charges payable)	-62	-70
6.01.02.15	Trading on operations	-2,469	-1,248
6.02	Net cash used in investment activities	-30,560	-144,003
6.02.01	Acquisitions of property, plant and equipment	-135	-540
6.02.02	Development of systems and software use licenses	-13,327	-23,962
6.02.03	Acquisition of investment	0	-17,226
6.02.07	Dividends received from Subsidiaries and jointly-controlled subsidiaries	4,625	1,000
6.02.11	Interest earning bank deposits (Financial assets valued at amortized cost)	-21,723	-103,275
6.03	Net cash from financing activities	-19,580	0
6.03.01	Dividends and interest on own capital paid	-19,580	0
6.05	Increase (decrease) in cash and cash equivalents	-1,659	-5,257
6.05.01	Opening balance of cash and cash equivalents	13,615	14,815
6.05.02	Closing balance of cash and cash equivalents	11,956	9,558

Individual financial statements / Statement of changes in shareholders' equity / DMPL – 01/01/2024–03/31/2024**(In thousand of reais)**

Code of account	Account description	Paid-up capital	Capital reserves, Options granted and Treasury shares	Profit reserves	Retained earnings (loss)	Other comprehensive income	Shareholders' equity
5.01	Opening balances	851,017	-35,610	561,679	0	9,908	1,386,994
5.02	Prior-year adjustments	0	0	0	0	0	0
5.03	Adjusted opening balances	851,017	-35,610	561,679	0	9,908	1,386,994
5.04	Capital transactions with partners	0	-22,179	0	-22,779	0	-44,958
5.04.04	Treasury shares acquired	0	-22,179	0	0	0	-22,179
5.04.07	Interest on own capital	0	0	0	-22,779	0	-22,779
5.05	Total comprehensive income	0	0	0	146,737	-4,126	142,611
5.05.01	Net income for the period	0	0	0	146,737	0	146,737
5.05.02	Other comprehensive income	0	0	0	0	-4,126	-4,126
5.05.02.04	Translation adjustments in the period	0	0	0	0	571	571
5.05.02.06	Equity valuation adjustments of investees recognized under the equity method	0	0	0	0	7	7
5.05.02.08	Other comprehensive income	0	0	0	0	-4,636	-4,636
5.05.02.09	Other comprehensive income of investees recognized under the equity method	0	0	0	0	-68	-68
5.06	Internal changes in shareholders' equity	0	0	0	0	0	0
5.07	Closing balances	851,017	-57,789	561,679	123,958	5,782	1,484,647

Individual financial statements / Statement of changes in shareholders' equity / DMPL – 01/01/2024–03/31/2024**(In thousand of reais)**

Code of account	Account description	Paid-up capital	Capital reserves, Options granted and Treasury shares	Profit reserves	Retained earnings (loss)	Other comprehensive income	Shareholders' equity
5.01	Opening balances	851,017	-200,025	533,027	0	140	1,184,159
5.02	Prior-year adjustments	0	0	-28,375	0	-27,993	-56,368
5.03	Adjusted opening balances	851,017	-200,025	504,652	0	-27,853	1,127,791
5.04	Capital transactions with partners	0	1,411	0	-21,239	0	-19,828
5.04.07	Interest on own capital	0	0	0	-21,239	0	-21,239
5.04.08	Goodwill/negative goodwill in capital transaction	0	424	0	0	0	424
5.04.19	Put option in Subsidiary	0	987	0	0	0	987
5.05	Total comprehensive income	0	0	0	139,722	-26,494	113,228
5.05.01	Net income for the period	0	0	0	139,722	0	139,722
5.05.02	Other comprehensive income	0	0	0	0	-26,494	-26,494
5.05.02.04	Translation adjustments in the period	0	0	0	0	1,406	1,406
5.05.02.06	Other comprehensive income of investees recognized under the equity method	0	0	0	0	-950	-950
5.05.02.08	Other comprehensive income	0	0	0	0	-26,950	-26,950
5.06	Internal changes in shareholders' equity	0	0	0	0	0	0
5.07	Closing balances	851,017	-198,614	504,652	118,483	-54,347	1,221,191

Individual financial statements / Statement of added value**(In thousand of reais)**

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2024–03/31/2024	01/01/2023–03/31/2023
7.01	Revenues	531,247	491,166
7.01.01	Sale of goods, products and services	531,106	491,127
7.01.04	Formation/reversal of allowance for doubtful accounts	141	39
7.02	Inputs acquired from third parties	-268,940	-244,613
7.02.01	Cost of products, goods and services sold	-220,768	-210,467
7.02.02	Materials, energy, third-party services and other	-4,706	-3,590
7.02.04	Other	-43,466	-30,556
7.02.04.01	Other operating revenues (expenses)	-3,300	10,669
7.02.04.03	Administrative expenses	-40,166	-41,225
7.03	Gross added value	262,307	246,553
7.04	Retentions	-12,051	-9,807
7.04.01	Depreciation, amortization and depletion	-11,591	-9,360
7.04.02	Other	-460	-447
7.04.02.01	Amortization of right-of-use (CPC 06 (R2)/IFRS 16)	-460	-447
7.05	Net added value produced	250,256	236,746
7.06	Added value received as transfer	41,226	31,230
7.06.01	Equity in net income of subsidiaries	5,848	4,910
7.06.02	Financial revenues	35,378	26,320
7.07	Total added value payable	291,482	267,976
7.08	Distribution of added value	291,482	267,976
7.08.01	Personnel	38,498	36,295
7.08.01.01	Direct remuneration	30,020	29,262
7.08.01.02	Benefits	6,719	5,449
7.08.01.03	SEVERANCE PAY FUND (FGTS)	1,759	1,584
7.08.02	Taxes, duties and contributions	94,176	89,288
7.08.02.01	Federal	86,184	80,824
7.08.02.02	State	17	20
7.08.02.03	Municipal	7,975	8,444
7.08.03	Third-party capital remuneration	12,071	2,671
7.08.03.02	Rentals	187	56
7.08.03.03	Other	11,884	2,615
7.08.03.03.01	Financial expenses	11,884	2,615
7.08.04	Remuneration of own capital	146,737	139,722
7.08.04.01	Interest on own capital	22,779	21,239
7.08.04.03	Retained earnings / Loss for the period	123,958	118,483

Consolidated financial statements / Balance sheet - Liabilities**(In thousand of reais)**

Code of account	Account description	Current quarter 03/31/2024	Prior year 12/31/2023
1	Total assets	2,329,279	2,163,973
1.01	Current assets	651,243	517,175
1.01.01	Cash and cash equivalents	12,852	14,391
1.01.02	Interest earning bank deposits	525,417	357,633
1.01.02.01	Interest earning bank deposits measured at fair value through profit or loss	376,497	208,903
1.01.02.01.04	Free investments	376,497	208,903
1.01.02.03	Interest earning bank deposits measured at amortized cost	148,920	148,730
1.01.02.03.01	Investments that guarantee technical reserves	19,949	20,060
1.01.02.03.02	Free investments	128,971	128,670
1.01.03	Accounts receivable	88,119	119,586
1.01.03.01	Clients	46,160	32,912
1.01.03.01.06	Assets of insurance and reinsurance contracts	46,160	32,912
1.01.03.02	Other accounts receivable	41,959	86,674
1.01.03.02.01	Advances to suppliers and others	857	839
1.01.03.02.02	Advances to employees	10,102	10,485
1.01.03.02.03	Other Credits Receivable	31,000	75,350
1.01.04	Inventories	1	1,423
1.01.06	Recoverable taxes	15,337	12,922
1.01.06.01	Current taxes recoverable	15,337	12,922
1.01.06.01.01	Tax and social security credits	15,337	12,922
1.01.07	Prepaid expenses	3,427	5,130
1.01.07.20	Other	3,427	5,130
1.01.08	Other current assets	6,090	6,090
1.01.08.01	Non-current assets held for sale	6,090	6,090
1.02	Non-current assets	1,678,036	1,646,798
1.02.01	Non-current receivables	738,452	705,736
1.02.01.03	Interest earning bank deposits measured at amortized cost	641,658	620,125
1.02.01.03.01	Investments that guarantee technical reserves	173,094	173,839
1.02.01.03.02	Free investments	468,564	446,286
1.02.01.07	Deferred taxes	24,691	15,192
1.02.01.07.01	Deferred income tax and social contribution	24,691	15,192
1.02.01.10	Other non-current assets	72,103	70,419
1.02.01.10.03	Judicial and tax deposits	31,590	30,481
1.02.01.10.04	Other credits receivable	15,800	15,751
1.02.01.10.06	Tax and social security credits (recoverable taxes)	24,713	24,187
1.02.02	Investments	5,713	6,350
1.02.02.01	Equity interest	5,713	6,350
1.02.03	Property, plant and equipment	51,693	55,060
1.02.03.01	Construction in progress	26,690	28,477
1.02.03.01.01	Property, plant and equipment for use	19,421	20,799
1.02.03.01.02	Other fixed assets	7,269	7,678
1.02.03.02	Right-of-use in lease	25,003	26,583
1.02.03.02.01	Right-of-use (CPC 06 (R2)/IFRS 16)	25,003	26,583
1.02.04	Intangible assets	882,178	879,652

Consolidated financial statements / Balance sheet - Liabilities**(In thousand of reais)**

Code of account	Account description	Current quarter 03/31/2024	Prior year 12/31/2023
1.02.04.01	Intangible assets	882,178	879,652
1.02.04.01.02	Goodwill on acquisition of investments	669,469	669,469
1.02.04.01.03	Development of systems, software use licenses	184,931	180,547
1.02.04.01.05	Allocated intangible assets	27,778	29,636

Consolidated financial statements / Balance sheet - Liabilities**(In thousand of reais)**

Code of account	Account description	Current quarter 03/31/2024	Prior year 12/31/2023
2	Total liabilities	2,329,279	2,163,973
2.01	Current liabilities	709,145	648,332
2.01.01	Social and labor obligations	79,878	72,688
2.01.01.01	Social charges	8,125	9,163
2.01.01.01.01	Charges payable	8,125	9,163
2.01.01.02	Labor obligations	71,753	63,525
2.01.01.02.01	Salaries, vacation and fees	71,753	63,525
2.01.02	Suppliers	27,278	29,289
2.01.02.01	Domestic suppliers	27,278	29,289
2.01.02.01.01	Trading on operations	4,648	7,115
2.01.02.01.02	Suppliers of goods and services	17,041	16,475
2.01.02.01.04	Consideration/premiums to be repaid	135	53
2.01.02.01.05	Lease liabilities (CPC 06 (R2)/IFRS 16)	7,593	7,905
2.01.02.01.06	Adjustment to present value - lease liabilities (CPC 06 (R2)/IFRS 16)	-2,139	-2,259
2.01.03	Tax liabilities	41,754	25,570
2.01.03.01	Federal tax liabilities	38,182	21,719
2.01.03.01.01	Income tax and social contribution payable	21,150	4,590
2.01.03.01.02	Other federal tax liabilities	17,032	17,129
2.01.03.02	State tax liabilities	2	148
2.01.03.03	Municipal tax liabilities	3,570	3,703
2.01.05	Other liabilities	264,471	243,224
2.01.05.02	Other	264,471	243,224
2.01.05.02.01	Dividends and interest on own capital	19,425	16,813
2.01.05.02.02	Minimum mandatory dividend payable	184,761	184,761
2.01.05.02.04	Advances from clients	1,142	826
2.01.05.02.05	Other accounts payable	31,653	35,616
2.01.05.02.06	Repurchase of shares payable	22,185	0
2.01.05.02.08	Investments payable	5,305	5,208
2.01.06	Provisions	295,764	277,561
2.01.06.02	Other provisions	295,764	277,561
2.01.06.02.09	Liabilities of insurance and reinsurance contracts	295,764	277,561
2.02	Non-current liabilities	134,961	127,967
2.02.02	Other liabilities	68,989	64,760
2.02.02.02	Other	68,989	64,760
2.02.02.02.03	Other liabilities	16,838	16,683
2.02.02.02.04	Fees payable	0	97
2.02.02.02.06	Investments payable	4,076	4,063
2.02.02.02.07	Lease liabilities (CPC 06 (R2)/IFRS 16)	26,824	28,481
2.02.02.02.08	Adjustment to present value - lease liabilities (CPC 06 (R2)/IFRS 16)	-4,386	-4,832
2.02.02.02.09	Long-term incentive (ILP)	25,637	20,268
2.02.04	Provisions	65,972	63,207
2.02.04.01	Tax, social security, labor and civil provision	38,894	36,966
2.02.04.01.01	Tax provision	1,929	1,917
2.02.04.01.02	Social security and labor provisions	2,688	2,993

Consolidated financial statements / Balance sheet - Liabilities**(In thousand of reais)**

Code of account	Account description	Current quarter 03/31/2024	Prior year 12/31/2023
2.02.04.01.04	Civil provision	34,277	32,056
2.02.04.02	Other provision	27,078	26,241
2.02.04.02.04	Installment payments of taxes and contributions	363	375
2.02.04.02.05	Taxes and charges payable	26,715	25,866
2.03	Consolidated shareholders' equity	1,485,173	1,387,674
2.03.01	Realized capital	851,017	851,017
2.03.02	Capital reserves	-35,610	-35,610
2.03.02.10	Goodwill/negative goodwill in capital transaction	-35,610	-35,610
2.03.04	Profit reserves	539,500	561,679
2.03.04.01	Legal reserve	100,749	100,749
2.03.04.07	Tax incentive reserve	129	129
2.03.04.08	Additional dividend proposed	242,492	242,492
2.03.04.09	Treasury shares	-22,179	0
2.03.04.10	Statutory Reserve of Regulatory Capital	100,000	100,000
2.03.04.11	Investment and expansion reserve	60,373	60,373
2.03.04.12	First Investment Reserve	57,936	57,936
2.03.05	Retained earnings/losses	123,958	0
2.03.06	Equity valuation adjustments	-793	-800
2.03.07	Accumulated translation adjustments	2,580	2,009
2.03.08	Other comprehensive income	3,995	8,699
2.03.09	Non-controlling interest	526	680

Consolidated financial statements / Statement of income**(In thousand of reais)**

Code of account	Account description	Accumulated of the current year 01/01/2024–03/31/2024	Accumulated of the prior year 01/01/2023–03/31/2023
3.01	Revenue from sales of goods and/or services	554,501	500,893
3.01.02	Sales of goods and services	13,871	11,056
3.01.05	Taxes on sales of goods and services	-3,623	-4,356
3.01.07	Insurance revenue (PAA)	422,880	388,316
3.01.08	Insurance revenue (BBA)	121,373	105,877
3.02	Cost of goods and/or services sold	-359,678	-329,744
3.02.08	Insurance costs	-359,678	-329,744
3.03	Gross income	194,823	171,149
3.04	Operating expenses/revenue	-7,575	5,671
3.04.02	General and administrative expenses	-15,016	-7,005
3.04.02.01	Administrative expenses	-13,264	-6,466
3.04.02.02	Amortization of right-of-use (CPC 06 (R2)/IFRS 16)	-1,207	-479
3.04.02.03	Rentals	-662	-622
3.04.02.04	Rents (CPC 06 (R2)/IFRS 16)	442	562
3.04.02.05	Income (loss) from disposal or write-off of non-current asset items and other	-325	0
3.04.04	Other operating revenue	13,292	18,554
3.04.04.01	Other operating revenues from Health care plans	13,173	18,451
3.04.04.02	Health care revenues not related to the Operator's health plans	119	103
3.04.05	Other operating expenses	-6,907	-7,518
3.04.05.02	Provision for credit losses	112	-501
3.04.05.03	Profit sharing	-6,620	-6,660
3.04.05.04	Long-term incentive program (ILP)	-399	-357
3.04.06	Equity in net income of subsidiaries	1,056	1,640
3.05	Income (loss) before financial income and taxes	187,248	176,820
3.06	Financial income (loss)	23,625	24,265
3.06.01	Financial revenues	36,246	27,463
3.06.01.01	Financial revenues	36,246	27,463
3.06.02	Financial expenses	-12,621	-3,198
3.06.02.01	Financial expenses	-12,003	-2,797
3.06.02.02	Adjustment to present value - lease liabilities (CPC 06 (R2)/IFRS 16)	-618	-401
3.07	Income (loss) before income tax	210,873	201,085
3.08	Income tax and social contribution	-64,184	-61,417
3.08.01	Current	-71,156	-75,523
3.08.02	Deferred	6,972	14,106
3.09	Net income (loss) from continued operations	146,689	139,668
3.11	Income/loss for the period	146,689	139,668
3.11.01	Attributed to the Parent company's partners	146,737	139,722
3.11.02	Attributed to non-controlling partners	-48	-54
3.99	Earnings per share - (Reais R\$ / Shares)		
3.99.01	Basic earnings per share		
3.99.01.01	COMMON SHARES	0.26559	0.25289
3.99.02	Diluted earnings per share		

Consolidated financial statements / Statement of income**(In thousand of reais)**

Code of account	Account description	Accumulated of the current year 01/01/2024–03/31/2024	Accumulated of the prior year 01/01/2023–03/31/2023
3.99.02.01	COMMON SHARES	0.26559	0.25289

Consolidated financial statements / Statement of comprehensive income**(In thousand of reais)**

Code of account	Account description	Accumulated of the current year	Accumulated of the prior year
		01/01/2024–03/31/2024	01/01/2023–03/31/2023
4.01	Consolidated net income for the period	146,689	139,668
4.02	Other comprehensive income	5,782	-53,726
4.02.01	Accumulated translation adjustment	2,710	2,009
4.02.02	Gain and losses from changes in equity interest	-923	-800
4.02.03	Other comprehensive income of investees recognized under the equity method	-54	-485
4.02.04	Other comprehensive income	4,049	-54,450
4.03	Consolidated comprehensive income for the period	152,471	85,942
4.03.01	Attributed to the Parent company's partners	152,519	85,996
4.03.02	Attributed to non-controlling partners	-48	-54

Consolidated financial statements / Statement of cash flows (Indirect method)**(In thousand of reais)**

Code of account	Account description	Accumulated of the current year 01/01/2024–03/31/2024	Accumulated of the prior year 01/01/2023–03/31/2023
6.01	Net cash from operational activities	52,026	140,932
6.01.01	Cash generated in operations	221,329	222,552
6.01.01.01	Net income (loss) for the period	146,689	139,668
6.01.01.02	Depreciation and amortization	12,678	10,612
6.01.01.03	Net inflation adjustments	-2,816	10,318
6.01.01.05	Provision for lawsuits (Contingencies)	488	-1,198
6.01.01.06	Income (loss) from disposal of non-current assets and other	325	0
6.01.01.07	Equity in net income of subsidiaries	-1,056	-1,640
6.01.01.08	Provision for credit losses	-112	501
6.01.01.11	Provision for income tax and social contribution	64,184	61,417
6.01.01.13	Amortization of right-of-use (CPC 06 (R2)/IFRS 16)	1,667	926
6.01.01.14	Rents (CPC 06 (R2)/IFRS 16)	-1,115	-1,134
6.01.01.15	Adjustment to present value - lease liabilities (CPC 06 (R2)/IFRS 16)	618	401
6.01.01.16	Unearned revenue (CPC 47/IFRS 15)	-221	2,681
6.01.02	Changes in assets and liabilities	-169,303	-81,620
6.01.02.01	Interest earning bank deposits (Financial assets at fair value through profit or loss)	-167,594	-19,533
6.01.02.03	Other accounts receivable, recoverable taxes and prepaid expenses	44,003	-6,199
6.01.02.04	Inventories	1,422	-121
6.01.02.05	Non-current receivables	2,526	-2,291
6.01.02.06	Assets and liabilities of insurance and reinsurance contracts	-1,955	46,813
6.01.02.09	Tax obligations (taxes payable)	-376	-1,182
6.01.02.10	Labor obligations, Suppliers, Advance from clients and Other accounts payable (Sundry debits)	4,617	-22,130
6.01.02.11	Non-current liabilities	6,296	-2,347
6.01.02.13	Income tax and social contribution paid	-54,737	-73,451
6.01.02.14	Social charges	-1,038	64
6.01.02.15	Trading on operations	-2,467	-1,243
6.02	Net cash used in investment activities	-33,839	-145,760
6.02.01	Acquisitions of property, plant and equipment	-397	-1,932
6.02.02	Development of systems and software use licenses	-13,344	-24,327
6.02.06	Acquisition of investment	0	-17,226
6.02.07	Dividends received from Subsidiaries and jointly-controlled subsidiaries	1,625	1,000
6.02.11	Interest earning bank deposits (Financial assets valued at amortized cost)	-21,723	-103,275
6.03	Net cash from financing activities	-19,726	0
6.03.01	Dividends and interest on own capital paid	-19,726	0
6.05	Increase (decrease) in cash and cash equivalents	-1,539	-4,828
6.05.01	Opening balance of cash and cash equivalents	14,391	15,837
6.05.02	Closing balance of cash and cash equivalents	12,852	11,009

Consolidated financial statements / Statement of changes in shareholders' equity / DMPL – 01/01/2024–03/31/2024**(In thousand of reais)**

Code of account	Account description	Paid-up capital	Capital reserves, Options granted and Treasury shares	Profit reserves	Retained earnings (loss)	Other comprehensive income	Shareholders' equity	Non-controlling interest	Consolidated shareholders' equity
5.01	Opening balances	851,017	-35,610	561,679	0	9,908	1,386,994	680	1,387,674
5.02	Prior-year adjustments	0	0	0	0	0	0	0	0
5.03	Adjusted opening balances	851,017	-35,610	561,679	0	9,908	1,386,994	680	1,387,674
5.04	Capital transactions with partners	0	-22,179	0	-22,779	0	-44,958	0	-44,958
5.04.04	Treasury shares acquired	0	-22,179	0	0	0	-22,179	0	-22,179
5.04.07	Interest on own capital	0	0	0	-22,779	0	-22,779	0	-22,779
5.05	Total comprehensive income	0	0	0	146,737	-4,126	142,611	-154	142,457
5.05.01	Net income for the period	0	0	0	146,737	0	146,737	-48	146,689
5.05.02	Other comprehensive income	0	0	0	0	-4,126	-4,126	-106	-4,232
5.05.02.04	Translation adjustments in the period	0	0	0	0	571	571	0	571
5.05.02.07	Gain and losses from changes in equity interest	0	0	0	0	7	7	0	7
5.05.02.08	Other comprehensive income	0	0	0	0	-4,636	-4,636	-106	-4,742
5.05.02.09	Other comprehensive income of investees recognized under the equity method	0	0	0	0	-68	-68	0	-68
5.06	Internal changes in shareholders' equity	0	0	0	0	0	0	0	0
5.07	Closing balances	851,017	-57,789	561,679	123,958	5,782	1,484,647	526	1,485,173

Consolidated financial statements / Statement of changes in shareholders' equity / DMPL – 01/01/2024–03/31/2024**(In thousand of reais)**

Code of account	Account description	Paid-up capital	Capital reserves, Options granted and Treasury shares	Profit reserves	Retained earnings (loss)	Other comprehensive income	Shareholders' equity	Non-controlling interest	Consolidated shareholders' equity
5.01	Opening balances	851,017	-200,025	533,027	0	140	1,184,159	1,359	1,185,518
5.02	Prior-year adjustments	0	0	-28,375	0	-27,993	-56,368	0	-56,368
5.03	Adjusted opening balances	851,017	-200,025	504,652	0	-27,853	1,127,791	1,359	1,129,150
5.04	Capital transactions with partners	0	1,411	0	-21,239	0	-19,828	0	-19,828
5.04.07	Interest on own capital	0	0	0	-21,239	0	-21,239	0	-21,239
5.04.08	Goodwill/negative goodwill in capital transaction	0	424	0	0	0	424	0	424
5.04.19	Put option in Subsidiary	0	987	0	0	0	987	0	987
5.05	Total comprehensive income	0	0	0	139,722	-26,494	113,228	-889	112,339
5.05.01	Net income for the period	0	0	0	139,722	0	139,722	-54	139,668
5.05.02	Other comprehensive income	0	0	0	0	-26,494	-26,494	-835	-27,329
5.05.02.04	Translation adjustments in the period	0	0	0	0	1,406	1,406	0	1,406
5.05.02.07	Gain and losses from changes in equity interest	0	0	0	0	-950	-950	0	-950
5.05.02.08	Other comprehensive income	0	0	0	0	-26,950	-26,950	-835	-27,785
5.06	Internal changes in shareholders' equity	0	0	0	0	0	0	0	0
5.07	Closing balances	851,017	-198,614	504,652	118,483	-54,347	1,221,191	470	1,221,661

Consolidated financial statements / Statement of added value**(In thousand of reais)**

Code of account	Account description	Accumulated of the current year 01/01/2024–03/31/2024	Accumulated of the prior year 01/01/2023–03/31/2023
7.01	Revenues	558,236	504,748
7.01.01	Sale of goods, products and services	544,253	494,193
7.01.02	Other revenues	13,871	11,056
7.01.02.02	Sales of goods and services	13,871	11,056
7.01.04	Formation/reversal of allowance for doubtful accounts	112	-501
7.02	Inputs acquired from third parties	-262,472	-227,465
7.02.01	Cost of products, goods and services sold	-219,987	-208,172
7.02.02	Materials, energy, third-party services and other	-5,867	-2,794
7.02.04	Other	-36,618	-16,499
7.02.04.01	Other operating revenues (expenses)	-3,965	9,899
7.02.04.03	Administrative expenses	-32,653	-26,398
7.03	Gross added value	295,764	277,283
7.04	Retentions	-14,345	-11,538
7.04.01	Depreciation, amortization and depletion	-12,678	-10,612
7.04.02	Other	-1,667	-926
7.04.02.01	Amortization of right-of-use (CPC 06 (R2)/IFRS 16)	-1,667	-926
7.05	Net added value produced	281,419	265,745
7.06	Added value received as transfer	37,302	29,103
7.06.01	Equity in net income of subsidiaries	1,056	1,640
7.06.02	Financial revenues	36,246	27,463
7.07	Total added value payable	318,721	294,848
7.08	Distribution of added value	318,721	294,848
7.08.01	Personnel	56,543	53,124
7.08.01.01	Direct remuneration	43,480	42,283
7.08.01.02	Benefits	10,366	8,411
7.08.01.03	SEVERANCE PAY FUND (FGTS)	2,697	2,430
7.08.02	Taxes, duties and contributions	102,461	98,742
7.08.02.01	Federal	92,987	88,503
7.08.02.02	State	113	442
7.08.02.03	Municipal	9,361	9,797
7.08.03	Third-party capital remuneration	13,028	3,314
7.08.03.02	Rentals	407	116
7.08.03.03	Other	12,621	3,198
7.08.03.03.01	Financial expenses	12,621	3,198
7.08.04	Remuneration of own capital	146,689	139,668
7.08.04.01	Interest on own capital	22,994	21,239
7.08.04.02	Dividends	82	0
7.08.04.03	Retained earnings / Loss for the period	123,661	118,483
7.08.04.04	Non-controlling interest in retained earnings	-48	-54

Performance comment

São Paulo, May 07, 2024

Odontoprev (B3: ODPV3 BZ), Brazil's largest dental plan operator, announces today its consolidated results for the first quarter of 2024 (1Q24).

The information contained in the Quarterly Report (ITR), released to CVM/B3, include the IFRS 17, CPC 50 – Insurance Contracts and IFRS 9/CPC 48 – Financial Instruments were also applied.

The **performance comments** maintain the comparability of data from historical series, since 2006, and are based on standards approved by the National Supplementary Health Agency – ANS.

Below are the conciliation tables from the financial statements (Balance Sheet, Income Statement and Cash Flow) 1Q24 for IFRS 17 and calculating solvency.

Performance comment

Balance sheet

(in thousand reais)

	Consolidated		
	Balance at March 31, 2024 (ANSGAAP)	Effects (CPC 50/IFRS 17)	Balance at March 31, 2024 (CPC 50/IFRS 17)
ASSETS			
Current assets	744,493	(93,250)	651,243
Cash and cash equivalents	12,852	-	12,852
Interest earning bank deposits	525,417	-	525,417
Accounts receivable	146,331	(58,212)	88,119
Cash considerations/ Premiums receivable	96,065	(96,065)	-
Provision for credit losses	(23,122)	23,122	-
Participation of beneficiaries in indemnifying events/claims	1,853	(1,853)	-
Healthcare plan operators	8,948	(8,948)	-
Other receivables from operations with healthcare plans	27,655	(27,655)	-
Assets of insurance and reinsurance contracts	-	46,160	46,160
Other accounts receivable	34,932	7,027	41,959
Inventory	1	-	1
Recoverable taxes	15,337	-	15,337
Prepaid expenses	38,465	(35,038)	3,427
Other current assets	6,090	-	6,090
Non-current assets	1,653,553	24,483	1,678,036
Interest earning bank deposits valued at amortized cost	641,658	-	641,658
Deferred income tax and social contribution	-	24,691	24,691
Other non-current assets	72,103	-	72,103
Investments (ownership interest under the equity method)	5,921	(208)	5,713
Property, plant and equipment	51,693	-	51,693
Intangible assets	882,178	-	882,178
TOTAL ASSETS	2,398,046	(68,767)	2,329,279
LIABILITIES			
Current liabilities	715,457	(6,312)	709,145
Technical reserves for health care operations	306,590	(306,590)	-
Liabilities of insurance and reinsurance contracts	-	295,764	295,764
Debits from health care operations	6,247	(1,464)	4,783
Taxes and charges payable	49,879	-	49,879
Sundry debits	352,741	5,978	358,719
Non-current liabilities	139,898	(4,937)	134,961
Provision for lawsuits (Contingencies)	38,894	-	38,894
Taxes and social security charges payable	32,015	(4,937)	27,078
Sundry debits	68,989	-	68,989
Shareholders' equity	1,542,691	(57,518)	1,485,173
Realized capital	1,071,330	-	1,071,330
Capital reserves	(35,610)	-	(35,610)
Legal reserve	100,749	-	100,749
Tax incentive reserve	129	-	129
Investment and expansion statutory reserve	271,844	(111,471)	160,373
First Investment Reserve	-	57,936	57,936
Retained earnings and losses	132,606	(8,648)	123,958
Equity valuation adjustments	(793)	-	(793)
Accumulated translation adjustments	1,910	670	2,580
Other comprehensive income	-	3,995	3,995
Non-controlling interest	526	-	526
TOTAL LIABILITIES	2,398,046	(68,767)	2,329,279

Performance comment

Statement of income

(in thousands of reais)

	Balance at March 31, 2024 (ANSGAAP)	Effects (CPC 50/IFRS 17)	Consolidated Balance at March 31, 2024 (CPC 50/IFRS 17)
Net considerations/Retained premiums	540,101	(540,101)	-
Insurance	11,352	(11,352)	-
Insurance revenue (PAA)	-	422,880	422,880
Insurance revenue (BBA)	-	121,373	121,373
INSURANCE AND REINSURANCE REVENUES	551,453	(7,200)	544,253
Net indemnifiable events/retained claims	(152,311)	152,311	-
Changes in provision for events/claims incurred but Not Reported (PEONA)	1,280	(1,280)	-
Claims	(2,593)	2,593	-
Claims technical Reserves	225	(225)	-
Sales expenses	(60,534)	60,534	-
Direct taxes from operations with health care plans for the operator	(25,524)	25,524	-
Dental materials	(4,819)	4,819	-
Other operating costs	(18,016)	18,016	-
Insurance expenses	-	(359,678)	(359,678)
INSURANCE AND REINSURANCE EXPENSES	(262,292)	(97,386)	(359,678)
INCOME (LOSS) FROM INSURANCE AND REINSURANCE OPERATIONS	289,161	(104,586)	184,575
Sales of goods and services	13,871	-	13,871
Taxes on sales of goods and services	(3,623)	-	(3,623)
Provision for credit losses	(10,302)	10,414	112
Other operating revenues (expenses)	3,592	9,700	13,292
GROSS INCOME	292,699	(84,472)	208,227
Administrative expenses	(90,041)	75,025	(15,016)
Long-term incentive program (ILP)	(5,450)	5,051	(399)
Profit sharing	(6,620)	-	(6,620)
Net financial income (loss)	32,077	(8,452)	23,625
Financial revenues	36,246	-	36,246
Financial expenses	(4,169)	(8,452)	(12,621)
Financial expenses	(4,169)	(8,452)	(12,621)
Equity in net income of subsidiaries	1,276	(220)	1,056
INCOME (LOSS) BEFORE INCOME TAXES	223,941	(13,068)	210,873
Income tax and social contribution	(68,604)	4,420	(64,184)
NET INCOME FOR THE YEAR	155,337	(8,648)	146,689
Attributable to:			
Company's shareholders	155,385	(8,648)	146,737
Non-controlling interest	(48)	-	(48)
NET INCOME FOR THE YEAR	155,337	(8,648)	146,689

Performance comment

Statement of cash flow

(in thousands of reais)

	Balance at March 31, 2024 (ANSGAAP)	Effects (CPC 50/IFRS 17)	Consolidated Balance at March 31, 2024 (CPC 50/IFRS 17)
Net cash from operating activities	52,026	-	52,026
Cash generated in operations	249,887	(28,558)	221,329
Net income (loss) for the period	155,337	(8,648)	146,689
Depreciation and amortization	12,678	-	12,678
Net inflation adjustments	(2,816)	-	(2,816)
Provision for lawsuits (Contingencies)	488	-	488
Income (loss) from disposal of non-current assets and other	325	-	325
Equity in net income of subsidiaries	(1,276)	220	(1,056)
Provision for credit losses	10,302	(10,414)	(112)
Changes in provision for events/claims incurred but Not Reported (PEONA)	(1,280)	1,280	-
Provision for income tax and social contribution	68,604	(4,420)	64,184
Provision for unearned premiums (UP)/considerations	6,801	(6,801)	-
Amortization of right-of-use (CPC 06 (R2)/IFRS 16)	1,667	-	1,667
Rents (CPC 06 (R2)/IFRS 16)	(1,115)	-	(1,115)
Adjustment to present value - lease liabilities (CPC 06 (R2)/IFRS 16)	618	-	618
Unearned revenue (CPC 47/IFRS 15)	(221)	-	(221)
Changes in technical claims reserves	(225)	225	-
Changes in assets and liabilities	(197,861)	28,558	(169,303)
Interest earning bank deposits (Financial assets at fair value through profit or loss)	(167,594)	-	(167,594)
Receivables from operations with healthcare plans (clients)	(27,324)	27,324	-
Other accounts receivable, recoverable taxes and prepaid expenses and other current assets	43,094	909	44,003
Inventories	1,422	-	1,422
Long-term assets (Non-current)	2,526	-	2,526
Assets and liabilities of insurance and reinsurance contracts	-	(1,955)	(1,955)
Provision for Unsettled claims (UC)	(5,591)	5,591	-
Tax obligations (taxes payable)	(376)	-	(376)
Labor obligations, Suppliers, Advance from clients and Other accounts payable (Sundry debits)	3,962	655	4,617
Non-current liabilities	6,296	-	6,296
Income tax and social contribution paid	(54,726)	(11)	(54,737)
Social charges (Charges payable)	(1,038)	-	(1,038)
Trading on operations	(2,285)	(182)	(2,467)
Other technical reserves (OTHER)	3,773	(3,773)	-
Net cash from investment activities	(33,839)	-	(33,839)
Acquisitions of property, plant and equipment	(397)	-	(397)
Development of systems and software use licenses	(13,344)	-	(13,344)
Acquisition of investment	-	-	-
Dividends received from Subsidiaries and jointly-controlled subsidiaries	1,625	-	1,625
Interest earning bank deposits (Financial assets valued at amortized cost)	(21,723)	-	(21,723)
Net cash from financing activities	(19,726)	-	(19,726)
Dividends and Interest on own capital paid	(19,726)	-	(19,726)
Increase (decrease) in cash and cash equivalents	(1,539)	-	(1,539)
Opening balance of cash and cash equivalents	14,391	-	14,391
Closing balance of cash and cash equivalents	12,852	-	12,852

Performance comment

ANS establishes the rules for recognizing technical provisions and criteria for maintaining minimum shareholders' equity in accordance with RN 569/2022. As of 2023, the regulatory capital assessment must consider the highest of the following values: (i) base capital; and (ii) risk-based capital.

The risk-based regulatory capital model considers five risk categories, namely:

(a) Underwriting risk is the uncertainty measure related to an adverse economic position that goes against the operator's expectations at the time of preparing its underwriting policy regarding the uncertainties existing in the estimation of technical provisions and those related to pricing.

(b) Credit risk is the measure of uncertainty related to the probability of the counterparty to a transaction, or a debt issuer, not honoring, total or partially, its financial commitments, or having its credit risk classification changed.

(c) Operational risk is the measure of uncertainty that understands the risks related to internal procedures (loss resulting from inadequacies or failures in internal processes, people and systems).

(d) Legal risk is the measure of uncertainty related to the lack of a complete legal foundation; is the risk of non-compliance with applicable laws, rules, regulations, agreements, current practices or ethical standards, including the risk that the nature of the product/service provided may make the operator particularly vulnerable to litigation.

(e) Market risk is the measure of uncertainty related to exposure to losses arising from the volatility of asset prices, such as share prices, interest rates, exchange rates, commodity prices and property prices.

Performance comment

For comparability purposes, the required Sufficiency increased from R\$213 million on December 31, 2023 to R\$319 million on March 31, 2024.

	Company: calculation of PMA, PLA, MS and CBR	
	March 31, 2024	December 31, 2023
Reference capital	11,227	11,227
(x) K factor ¹	3.23%	3.23%
Adjusted minimum shareholders' equity (PMA)	363	363
Shareholders' equity	1,542,165	1,431,211
Ownership interest in regulated entities	(4,068)	(4,388)
Deferred acquisition costs	(35,038)	(34,627)
Prepaid expenses	(2,503)	(4,239)
Intangible assets	(859,536)	(856,743)
Goodwill from indirect interests	(14,532)	(14,532)
Adjusted shareholders' equity (PLA)	626,488	516,682
Risk-based capital (CBR)²	307,069	303,470
Required sufficiency (PLA ANS - CBR) - as of 2023	319,419	213,212

¹ Factor K corresponds to the classification: group dentistry, tertiary segment and region 1 as per appendix RN 569/2022;

² On December 31, 2023, the CBR value considers the use of reduced factors, as defined in art. 6th of RN n° 569/2022. As of December 31, 2022, the numbers follow RN 526

= underwriting risk (CRS) + credit (CRC) + operational and legal (CRO).

Performance comment

Operational and financial performance


Net operating revenue (NOR)

Net operating revenue (NOR)													
	1Q24		1Q23		Δ%	4Q23		Δ%	APR23-MAR24		APR22-MAR23		Δ%
	R\$ 000	% NOR	R\$ 000	% NOR		R\$ 000	% NOR		R\$ 000	% NOR	R\$ 000	% NOR	
(+) Payments, net	554,423	100.7	536,508	102.4	3.3	551,223	101.1	0.6	2,188,973	100.9	2,074,402	103.0	5.5
(+) Sales of services and products	13,871	2.5	11,056	2.1	25.5	14,131	2.6	(1.8)	54,370	2.5	26,106	1.3	108.3
(+) Odontored (México)	11,549	2.1	6,414	1.2	80.1	7,755	1.4	48.9	39,145	1.8	21,297	1.1	83.8
Gross operating revenue (GOR)	579,843	105.3	553,977	105.8	4.7	573,109	105.1	1.2	2,282,488	105.2	2,121,805	105.4	7.6
(-) Direct taxes on dental care operations	25,524	4.6	25,815	4.9	(1.1)	23,810	4.4	7.2	97,055	4.5	92,864	4.6	4.5
(-) Taxes on sales of services and products	3,623	0.7	4,356	0.8	(16.8)	4,092	0.8	(11.5)	15,849	0.7	14,970	0.7	5.9
Net operating revenue (NOR)	550,696	100.0	523,806	100.0	5.1	545,207	100.0	1.0	2,169,584	100.0	2,013,969	100.0	7.7

The consolidated net revenue (ROL) reached R\$550,696 in 1Q24, a YoY increase of 5.1%, highlighting (i) +3.3% in Payments, with a higher share of the PME product and (ii) other revenues, mainly related to Odontored (Mexico) and Papaiz (dental radiology), acquired in February/23.


Net revenue

R\$ million



Net revenues evolution per segment

R\$ million and % NOR



*Includes R\$ 78 million from other revenues


Performance comment

Consolidated Average Ticket

	1Q24	1Q23	Δ%	4T22	Δ%	APR23- MAR24	APR22- MAR23	Δ%
Payments, net R\$000 (A)	554,423	536,508	3.3	551,223	0.6	2,188,973	2,074,402	5.5
Average number of members (B)	8,626,009	8,291,274	4.0	8,268,703	4.3	8,449,355	8,110,514	4.2
Average ticket (R\$/member/month) (A/B)/# of months	21.42	21.57	(0.7)	21.43	-	21.59	21.31	1.3

The consolidated average ticket in 1Q24 was R\$21.42, 0.7% lower than 1Q23.

Average ticket consolidated and per business segment




Performance comment

Total number of members

Odontoprev reached 8,634,125 members in 1Q24, with a net addition of 16 thousand beneficiaries in the quarter and 370 thousand in the last twelve months.

The Corporate segment lost 3 thousand lives in 1Q24, due to the contract termination of a Bradesco Dental client with 59 thousand lives, given the new shareholding relationship with a direct competitor.

The non-corporate segments added 20 thousand lives in the quarter, with an increase of 26 thousand clients of Bradesco and a decrease of 6 thousand lives from retailers.



Bradesco Dental was the best-selling brand over the last years, reaching 49% of the total members, representing 43% of the corporate portfolio, 75% of SME and 46% of Individuals. Bradesco Dental net additions were 191 thousand LTM and 856 thousand in the last 36 months.

	Net additions			Portfolio 1Q24	% segment
	1Q22	1Q23	1Q24		
Total	(27,849)	(53,380)	16,232	8,634,125	100%
bradesco dental	55,545	20,618	(25,554)	4,260,852	49%
BRASILDENTAL	(21,134)	(11,620)	(1,403)	462,905	5%
Others ¹	(62,260)	(62,378)	43,189	3,910,368	45%
Corporate	11	(25,111)	(3,348)	6,104,496	100%
bradesco dental	31,860	5,471	(51,709)	2,647,583	43%
BRASILDENTAL	(18,648)	(5,534)	(1,265)	355,714	6%
Others ¹	(13,201)	(25,048)	49,626	3,101,199	51%
SME	4,696	(5,905)	12,896	1,564,162	100%
bradesco dental	12,023	11,992	15,059	1,168,366	75%
BRASILDENTAL	(669)	(2,164)	(929)	49,883	3%
Others ¹	(6,658)	(15,733)	(1,234)	345,913	22%
Individual Plans	(32,556)	(22,364)	6,684	965,467	100%
bradesco dental	11,662	3,155	11,096	444,903	46%
BRASILDENTAL	(1,817)	(3,922)	791	57,308	6%
Others ¹	(42,401)	(21,597)	(5,203)	463,256	48%

¹On Corporate and SME, includes Odontoprev, Odonto System and Mogidonto. On Individual Plans, also includes retail channels.

Performance comment

Cost of services and dental care ratio

Cost of services (ex IBNR) and dental loss ratio (% NOR)													
	1Q24		1Q23		Δ% p.p. NOR	4Q23		Δ% p.p. NOR	APR23-MAR24		APR22-MAR23		Δ% p.p. NOR
	R\$ 000	% NOR	R\$ 000	% NOR		R\$ 000	% NOR		R\$mil	% NOR	R\$ 000	% NOR	
Cost of services (ex IBNR)	192,062	34.9	178,813	34.1	0.8	219,585	40.3	(5.4)	862,553	39.8	803,547	39.9	(0.1)
Indemnifiable claims, net	166,634	30.3	166,644	31.8	(1.5)	192,535	35.3	(5.0)	775,146	35.7	747,628	37.1	(1.4)
Payroll charges on services	-	-	3	-	-	(3)	-	-	(3)	-	3	-	-
Dental materials	4,819	0.9	1,949	0.4	0.5	6,796	1.2	(0.3)	18,705	0.9	6,705	0.3	0.6
Other operational costs and Provisions/reversals	18,016	3.3	8,794	1.7	1.6	18,204	3.3	-	59,864	2.8	43,476	2.2	0.6
Odontored (México)	2,593	0.5	1,423	0.3	0.2	2,053	0.4	0.1	8,842	0.4	5,734	0.3	0.1

Historically, the cost of services in Q1 is seasonally lower, due to lower frequency during the vacation and summer periods.

For comparison purposes, the IBNR Provision (Incurred but not Reported) and technical reserves (Odontored), were excluded from the Cost of Services.


In 1Q24, the cost of services represented 34.9% of NOR, +0.8 p.p. over 1Q23, due to the reversal of the provision for individual plans for free choice of dentists in the amount of R\$4,641 in the first quarter of 2023. Excluding this effect, all segments showed a drop in Dental care ratios YoY.

In the last twelve months, the cost of services represented 39.8% of NOR, the same level observed since 2020, given the increasing participation of SME and individual plans, with a lower relative cost.

Dental care ratio %	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	APR23-MAR24
Corporate	50.2	51.4	56.3	52.5	50.7	50.9	42.1	46.5	49.9	51.4	51.2
Average	← 50.5% →						← 49.8% →				
SME	39.0	40.6	45.5	42.4	40.2	37.9	28.4	28.5	26.9	28.3	28.1
Average	← 38.4% →						← 28.0% →				
Individual Plans*	28.3	25.6	25.2	27.5	30.0	35.6	40.9	34.9	28.1	23.3	23.0
Average	← 32.1% →						← 27.3% →				
Consolidated	46.2	46.6	49.1	45.7	44.1	44.5	40.6	39.3	40.2	39.6	39.8
Average	← 45.0% →						← 39.7% →				

*Excludes the free choice plans provisions/reversal

Performance comment



The Dental care ratio (DCR) in the Corporate segment was 44.4% in 1Q24, 0.4 p.p. lower than 1Q23, and 51.2% over the last twelve months.

In the SME segment, the DCR 24.1% in the quarter, 0.1 p.p. lower than 1Q23, and 28.1% in the last twelve months.

In individual plans, the DCR in 1Q24 was 19.3%, 1.5 p.p. lower than the DCR in 1Q23 of 20.8% excluding the effect of the reversal of plans with free choice of dentists.

The consolidated DCR data does not include any adjustments.

Performance comment


Selling expenses

	1Q24	1Q23	Δ%	4Q23	Δ%	APR23-MAR24	APR22-MAR23	Δ%
Selling expenses (R\$ 000)	60,534	54,091	11.9	57,962	4.4	227,091	214,815	5.7
Selling expenses (% NOR)	11.0	10.3	0.7 p.p.	10.6	0.4 p.p.	10.5	10.7	(0.2 p.p.)

The selling expenses were R\$60,534 in 1Q24, 11.0% of NOR, 0.7 p.p. higher than 1Q23, and 0.2 p.p. more efficient in the last twelve months, with the growing participation of the banking channel (with lower acquisition costs) in the total customer portfolio.


Selling expenses

R\$ million and % NOR



Quarterly consolidated and per segment selling expenses

% NOR




Performance comment

Contribution margin

In the last twelve months, the corporate cost of service per member per month was R\$8.5, down from R\$9.0 in 2016. The deflation observed in the cost of services in recent years is justified by the permanent segmentation of the dentist network, continuous improvement in digital auditing processes (aimed at maximizing the technical quality of the services provided), as well as the new profile and frequency of SME and Individual members, which have a higher contribution margin. In the last twelve months, SME and Individual segments accounted for 43% of consolidated revenue and 52% of the company's contribution margin, with annual growth of 9% and 14%, respectively, since 2016.

Higher ticket and lower cost increase contribution margin



* Excludes free choice plans provisions/ reversal

Performance comment

Key Metrics per segment

Key metrics	Corporate							
	1Q24	1Q23	Δ%	4Q23	Δ%	ABR23-MAR24	ABR22-MAR23	Δ%
Net operating revenue (NOR)	300,928	284,129	5.9	300,065	0.3	1,186,826	1,115,656	6.4
Average ticket	17.10	16.82	1.7	17.05	0.3	17.15	16.72	2.6
Number of members (000)	6,104	5,863	4.1	6,108	(0.1)	6,104	5,863	4.1
Net additions (000)	(3)	(25)	-	53	-	241	193	-
Cost of services	133,624	127,362	4.9	152,400	(12.3)	607,362	561,013	8.3
Dental care ratio (%)	44.4	44.8	(0.4 p.p.)	50.8	(6.4 p.p.)	51.2	50.3	0.9 p.p.
Cost of services / member / month	7.29	7.22	1.0	8.35	(12.7)	8.46	8.11	4.3
Gross profit	167,304	156,767	6.7	147,665	13.3	579,464	554,643	4.5
Gross margin (%)	55.6	55.2	0.4 p.p.	49.2	6.4 p.p.	48.8	49.7	(0.9 p.p.)
Selling expenses	21,625	19,657	10.0	21,945	(1.5)	82,549	75,546	9.3
Selling expenses (%)	7.2	6.9	0.3 p.p.	7.3	(0.1 p.p.)	7.0	6.8	0.2 p.p.
Gross profit	145,679	137,110	6.3	125,720	15.9	496,916	479,097	3.7
Gross margin	48.4	48.3	0.1 p.p.	41.9	6.5 p.p.	41.9	42.9	(1.0 p.p.)

Key metrics	SME							
	1Q24	1Q23	Δ%	4Q23	Δ%	ABR23-MAR24	ABR22-MAR23	Δ%
Net operating revenue (NOR)	112,825	105,391	7.1	111,723	1.0	439,921	401,995	9.4
Average ticket	25.47	26.59	(4.2)	25.76	(1.1)	26.12	26.70	(2.2)
Number of members (000)	1,564	1,394	12.2	1,551	0.8	1,564	1,394	12.2
Net additions (000)	13	(6)	-	59	-	170	138	-
Cost of services	27,136	25,510	6.4	30,978	(12.4)	123,820	109,004	13.6
Dental care ratio (%)	24.1	24.2	(0.1 p.p.)	27.7	(3.6 p.p.)	28.1	27.1	1.0 p.p.
Cost of services / member / month	5.81	6.09	(4.6)	6.79	(14.4)	6.98	6.85	1.8
Gross profit	85,689	79,881	7.3	80,745	6.1	316,101	292,991	7.9
Gross margin (%)	75.9	75.8	0.1 p.p.	72.3	3.6 p.p.	71.9	72.9	(1.0 p.p.)
Selling expenses	13,593	12,747	6.6	13,292	2.3	52,458	50,829	3.2
Selling expenses (%)	12.0	12.1	(0.1 p.p.)	11.9	0.1 p.p.	11.9	12.6	(0.7 p.p.)
Gross profit	72,096	67,134	7.4	67,453	6.9	263,643	242,162	8.9
Gross margin	63.9	63.7	0.2 p.p.	60.4	3.5 p.p.	59.9	60.2	(0.3 p.p.)

Key metrics	Individual plans							
	1Q24	1Q23	Δ%	4Q23	Δ%	APR23-MAR24	APR22-MAR23	Δ%
Net operating revenue (NOR)	115,146	121,172	(5.0)	115,627	(0.4)	465,173	463,886	0.3
Average ticket	42.33	42.10	0.5	42.15	0.4	41.70	40.30	3.5
Number of members (000)	965	1,007	(4.1)	959	0.7	965	1,007	(4.1)
Net additions (000)	7	(22)	-	(20)	-	(41)	(23)	-
Cost of services	22,279	25,260	(11.8)	26,008	(14.3)	107,025	121,492	(11.9)
Dental care ratio (%)	19.3	20.8	(1.5 p.p.)	22.5	(3.2 p.p.)	23.0	26.2	(3.2 p.p.)
Cost of services / member / month	7.72	8.27	(6.7)	8.95	(13.7)	9.04	9.94	(9.0)
Gross profit	92,868	95,912	(3.2)	89,619	3.6	358,148	342,394	4.6
Gross margin (%)	80.7	79.2	1.5 p.p.	77.5	3.2 p.p.	77.0	73.8	3.2 p.p.
Selling expenses	23,654	21,481	10.1	22,385	5.7	89,580	87,827	2.0
Selling expenses (%)	20.5	17.7	2.8 p.p.	19.4	1.1 p.p.	19.3	18.9	0.4 p.p.
Gross profit	69,214	74,431	(7.0)	67,233	2.9	268,568	254,567	5.5
Gross margin	60.1	61.4	(1.3 p.p.)	58.1	2.0 p.p.	57.7	54.9	2.8 p.p.

* The data for the Individual plans segment excludes provisions/reversals of free choice plans occurred between 2020 and 2023.

Performance comment


Administrative expenses (G&A)

	1Q24		1Q23		Δ%	Δ% p.p. NOR	4Q23		Δ%	Δ% p.p. NOR	APR23-MAR24		APR22-MAR23		Δ%	Δ% p.p. NOR
	R\$ 000	% NOR	R\$ 000	% NOR			R\$ 000	% NOR			R\$mil	% ROL	R\$ 000	% NOR		
Personnel	44,011	8.0	43,231	8.3	1.8	(0.3)	54,369	10.0	(19.1)	(2.0)	185,314	8.5	164,257	8.2	12.8	0.3
Third parties services	18,501	3.4	13,545	2.6	36.6	0.8	21,889	4.0	(15.5)	(0.6)	77,357	3.6	60,349	3.0	28.2	0.6
Rentals and post services	7,052	1.3	8,092	1.5	(12.8)	(0.2)	14,515	2.7	(51.4)	(1.4)	42,885	2.0	35,729	1.8	20.0	0.2
Publicity and advertising	3,567	0.6	2,138	0.4	66.8	0.2	8,629	1.6	(58.7)	(1.0)	19,880	0.9	14,917	0.7	33.3	0.2
Taxes and fees	922	0.2	1,051	0.2	(12.2)	-	2,155	0.4	(57.2)	(0.2)	5,159	0.2	5,252	0.3	(1.8)	(0.1)
Others	1,643	0.3	(1,218)	(0.2)	(234.9)	0.5	3,906	0.7	(57.9)	(0.4)	9,243	0.4	15,069	0.7	(38.7)	(0.3)
G&A (adjusted at EBITDA base)	75,696	13.7	66,839	12.8	13.3	0.9	105,463	19.3	(28.2)	(5.6)	339,839	15.7	295,572	14.7	15.0	1.0
Depreciation and amortization	12,678	2.3	10,612	2.0	19.5	0.3	14,261	2.6	(11.1)	(0.3)	51,293	2.4	38,773	1.9	32.3	0.5
Amortization of utilization rights	1,667	0.3	926	0.2	80.0	0.1	2,808	0.5	(40.6)	(0.2)	7,339	0.3	4,064	0.2	80.6	0.1
(+) Mogidonto incorporation expenses	-	-	-	-	-	-	-	-	-	-	-	-	(0.4)	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-	-	-	346	-	-	-
Other services	-	-	-	-	-	-	-	-	-	-	-	-	381	-	-	-
G&A (not adjusted at EBITDA base)	14,345	2.6	11,538	2.2	24.3	0.4	17,069	3.1	(16.0)	(0.5)	58,631	2.7	43,564	2.2	-	0.5
Total administrative expenses (G&A)	90,041	16.4	78,377	15.0	14.9	1.4	122,532	22.5	(26.5)	(6.1)	398,472	18.4	339,136	16.8	17.5	1.6

The administrative expenses (G&A at adjusted EBITDA basis) were 13.7% of NOR in 1Q24, 0.9 p.p. higher than 1Q23.

G&A

R\$ million and % NOR



Performance comment

Allowance for doubtful receivables


	1Q24	1Q23	Δ%	4Q23	Δ%	APR23- MAR24	APR22- MAR23	Δ%
Allowance for doubtful receivables (R\$ 000)	10,302	12,624	(18.4)	10,409	(1.0)	47,678	49,331	(3.4)
Allowance for doubtful receivables (% NOR)	1.9	2.4	(0.5 p.p.)	1.9	-	2.2	2.4	(0.2 p.p.)

The allowance for doubtful receivables is calculated considering overdue invoices (60 days for Individual plans and 90 days for corporate plans), plus an average percentage of historical losses.

In the quarter, the allowance for doubtful receivables was 1.9% of NOR, 0.5 p.p. lower than 1Q23, same level as 4Q23.

Allowance for doubtful receivables

R\$ million and % NOR



Performance comment


EBITDA and adjusted EBITDA

	1Q24		1Q23		Y/Y %	Δ% p.p. NOR	4Q23		Q/Q %	Δ% p.p. NOR	APR23-MAR24		APR22-MAR23		Y/Y %	Δ% p.p. NOR
	R\$ 000	% NOR	R\$ 000	% NOR			R\$ 000	% NOR			R\$ 000	% NOR	R\$ 000	% NOR		
Net Income	155,385	28.2	169,637	32.4	(8.4)	(4.2)	126,296	23.2	23.0	5.0	522,302	24.1	460,350	22.9	13.5	1.2
(+) Current income and social contribution tax	70,270	12.8	69,051	13.2	1.8	(0.4)	43,746	8.0	60.6	4.8	191,287	8.8	184,982	9.2	3.4	(0.4)
(+) Deferred income and social contribution tax	(2,552)	(0.5)	1,129	0.2	(326.1)	(0.7)	3,269	0.6	(178.1)	(1.1)	13,987	0.6	6,960	0.3	101.0	0.3
(-) Financial income	33,394	6.1	27,463	5.2	21.6	0.9	29,928	5.5	11.6	0.6	113,282	5.2	93,183	4.6	21.6	0.6
(+) Financial expenses	4,169	0.8	4,209	0.8	(0.9)	-	11,456	2.1	(63.6)	(1.3)	25,091	1.2	20,637	1.0	21.6	0.2
(-) Participation of minority shareholders	48	-	54	-	(10.8)	-	(44)	-	(211.2)	-	(202)	-	353	-	(157.3)	-
(+) Depreciation and amortization	12,678	2.3	10,612	2.0	19.5	0.3	14,261	2.6	(11.1)	(0.3)	51,293	2.4	38,773	1.9	32.3	0.5
(+) Amortization of utilization rights	1,667	0.3	926	0.2	80.0	0.1	2,808	0.5	(40.6)	(0.2)	7,339	0.3	4,064	0.2	80.6	0.1
(-) Equity in subsidiaries	1,276	0.2	1,675	0.3	(23.8)	(0.1)	(1,396)	(0.3)	(191.4)	0.5	2,744	0.1	5,846	0.3	(53.1)	(0.2)
EBITDA	206,899	37.6	226,372	43.2	(8.6)	(5.6)	173,347	31.8	19.4	5.8	695,475	32.1	616,384	30.6	12.8	1.5
(+) Incurred But Not Reported Provision - IBNR	(1,280)	(0.2)	(13,958)	(2.7)	(90.8)	2.5	2,401	0.4	(153.3)	(0.6)	(9,348)	(0.4)	(1,716)	(0.1)	444.9	(0.3)
(+) Odontored - Technical reserves	(225)	-	237	-	(195.1)	-	532	0.1	(142.4)	(0.1)	346	-	283	-	22.4	-
(+) Brasidental EBITDA Pro Forma	1,643	0.3	1,947	0.4	(15.6)	(0.1)	2,085	0.4	(21.2)	(0.1)	7,430	0.3	8,602	0.4	(13.6)	(0.1)
(-) ISS reversal	-	-	-	-	-	-	-	-	-	-	(4,794)	(0.2)	-	-	-	(0.2)
(+) Acquisitions	-	-	-	-	-	-	-	-	-	-	-	-	346	-	(100.0)	-
(+) Other third parties services	-	-	-	-	-	-	-	-	-	-	-	-	381	-	(100.0)	-
(-) Reversal TSS/ ANS	(4,572)	(0.8)	-	-	-	(0.8)	-	-	-	(0.8)	(41,296)	(1.9)	-	-	-	(1.9)
(-) INSS reversal	-	-	(12,564)	(2.4)	(100.0)	2.4	-	-	-	-	-	-	(12,564)	(0.6)	(100.0)	0.6
Adjusted EBITDA	202,464	36.8	202,036	38.6	0.2	(1.8)	141,641	26.0	42.9	10.8	647,811	29.9	611,718	30.4	5.9	(0.5)

The adjusted EBITDA reached R\$202,464 in 1Q24, the same level as the previous year, with a margin of 36.8%. In the last twelve months, adjusted EBITDA was R\$647,811, with a margin of 29.9%.

Adjusted EBITDA

R\$ million and % NOR



Performance comment

Financial income


	1Q24		1Q23		Δ%	4Q23		Δ%	APR23-MAR24		APR22-MAR23		Δ%
	R\$ 000	% NOR	R\$ 000	% NOR		R\$ 000	% NOR		R\$ 000	% NOR	R\$ 000	% NOR	
	Net financial income	29,224	5.3	23,254	4.4	25.7	18,472	3.4	58.2	88,191	4.1	72,546	3.6
(+) Financial income	33,394	6.1	27,463	5.2	21.6	29,928	5.5	11.6	113,282	5.2	93,183	4.6	21.6
(-) Financial expenses	4,169	0.8	4,209	0.8	(0.9)	11,456	2.1	(63.6)	25,091	1.2	20,637	1.0	21.6

The net financial income was R\$29,224 in 1Q24, versus R\$23,254 in 1Q23.

During 6M21, the Company's financial portfolio was partially migrated from Current Assets to long-term Treasury bonds, being post-fixed (80%) and pre-fixed (20%), with the same credit risk profile. The new instruments are booked at their yield curve, minimizing the volatility of the consolidated portfolio, and will be hold to maturity. The Company does not make use of derivatives.

Financial income recent evolution

R\$ million



Performance comment

Income and social contribution taxes

	1Q24		1Q23		Δ%	4Q23		Δ%	APR23-MAR24		APR22-MAR23		Δ%
	R\$ 000	% NOR	R\$ 000	% NOR		R\$ 000	% NOR		R\$ 000	% NOR	R\$ 000	% NOR	
Taxes	67,718	12.3	70,180	13.4	(3.5)	47,015	8.6	44.0	205,274	9.5	191,942	9.5	6.9
(-) Current income and social contribution taxes	70,270	12.8	69,051	13.2	1.8	43,746	8.0	60.6	191,287	8.8	184,982	9.2	3.4
(-) Deferred income and social contribution taxes	(2,552)	(0.5)	1,129	0.2	(326.1)	3,269	0.6	-	13,987	0.6	6,960	0.3	101.0

Effective tax rates

Effective tax rates					
(R\$000, except otherwise specified)	1Q24	1Q23	4Q23	APR23-MAR24	APR22-MAR23
Income before taxes and profit sharing	218,482	227,199	136,632	681,686	639,375
(-) Profit sharing	6,620	6,660	6,938	34,254	27,651
(=) Tax base	211,862	220,539	129,695	647,432	611,724
Taxes					
(-) Current income and social contribution taxes	70,270	69,051	43,746	191,287	184,982
(-) Deferred income and social contribution taxes	(2,552)	1,129	3,269	13,987	6,960
Total taxes	67,718	70,180	47,015	205,274	191,942
Current effective tax rate (% NOR)	33.2%	31.3%	33.7%	29.5%	30.2%

Goodwill

Goodwill balance for future profitability resulting from the acquisition and subsequent merger of the companies Mogidonto (R\$8,953) and Rede Dental (R\$4,327) to be excluded from the calculation of taxable income at the rate of 1/60th for each month of the calculation period.

Goodwill amortization schedule from 2024*	
Period	Total amortization R\$000
2024	4,296
2025	5,728
2026	3,256
Total	13,280

*Includes the difference between all amounts paid and the fair value of assets and liabilities of investments acquired and evaluated through a Purchase Price Allocation (PPA) assessment.

Performance comment

Net income

	1Q24	1Q23	Δ%	4Q23	Δ%	APR23- MAR24	APR22- MAR23	Δ%
Net income (R\$ 000)	155,385	169,637	(8.4)	126,296	23.0	522,302	460,350	13.5
Net margin (% NOR)	28.2	32.4	(4.2 p.p.)	23.2	5.0 p.p.	24.1	22.9	1.2 p.p.


Net income amounted to R\$155,385 in 1Q24, down 8.4% on 1Q23. In the quarter there was R\$5,458 related to the favorable decision in a lawsuit over the payment of INSS (see page 43). Excluding this effect, net income would have been R\$150,813, or 4.0% lower than the 1Q23 recurring net income of R\$157,074.

R\$ 000	1Q24	Extraordinary event	1Q24 recurring
Net operating revenue (NOR)	550,696	-	550,696
Other operating revenues	2,886	2,606	280
Net financial income	32,077	2,853	29,224
Income before taxes	223,941	5,458	218,482
Net income	155,385	4,572	150,813

Since 2020, net income has a CAGR of 12%.

Net income and net margin

R\$ million and % NOR



Performance comment

Summary of non-recurring events

R\$000	1Q24 ANS	New ANS CoA	México	INSS	1Q24
(+) Payments net	540,101	14,322	-	-	554,423
(+) Odontored (México)	11,352	-	197	-	11,549
Gross operating revenue	565,324	14,322	197	-	579,843
Net operating revenue	536,177	14,322	197	-	550,696
(-) Cost of services	176,234	14,322	-	-	190,556
Gross profit	359,943	-	197	-	360,139
(-) Selling expenses	60,534	-	-	-	60,534
(+) Other operating revenues	3,592	-	(197)	(2,606)	790
(-) General and Administrative Expenses	90,041	-	-	-	90,041
(-) Other operating expenses	22,372	-	-	-	22,372
Allowance for doubtful receivables	10,302	-	-	-	10,302
(+) Equity in subsidiaries	1,276	-	-	-	1,276
Income before financial income (expenses) and taxes	191,864	-	-	(2,606)	189,258
(+) Net financial income	32,077	-	-	(2,852)	29,224
(+) Financial income	36,246	-	-	(2,852)	33,394
(-) Financial expenses	4,169	-	-	-	4,169
Income before taxes	223,941	-	-	(5,458)	218,482
(-) Income and social contribution tax	68,604	-	-	(886)	67,718
Net income before participation of minority shareholders	155,337	-	-	(4,572)	150,764
(+) Participation of minority shareholders	48	-	-	-	48
(+) Total net adjustments	-	-	-	(4,572)	(4,572)
Net income	155,385	-	-	-	155,385

ANS' new charting of accounts 2022: The National Supplementary Health Agency (ANS), in 2022, published a new chart of accounts that changes the understanding of revenues and costs of post-managed corporate plans.

Mexico: revenue from services from a subsidiary which is classified in the "Other operating revenues" line in the chart of accounts by the local regulator ("Comisión Nacional de Seguros y Fianzas").

INSS: Odontoprev was successful in a court case, which became final, and secured the right to offset in 1Q24 the social security contributions collected by Rede Dental (incorporated in 2021) on payments made to individual dentists between the periods of October 2007 to October 2019.


Performance comment

Cash Flow

(R\$000)	1Q24	1Q23
CASH FLOW FROM OPERATIONAL ACTIVITIES		
Net income for the period	155,337	169,583
Reconciliation of net income with the cash generated by operations	94,550	108,716
NET CASH FROM OPERATIONAL ACTIVITIES	249,887	278,299
Decrease (increase) in operational assets	19,718	(28,263)
Increase (decrease) in operational liabilities	(49,985)	(89,571)
NET CASH PROVIDED BY (USED IN) OPERATIONAL ACTIVITIES	219,620	160,465
CASH FLOW FROM INVESTING ACTIVITIES		
Acquisition of property and equipment	(397)	(1,932)
System development, software licenses and other	(13,344)	(24,327)
Deferred selling expenses	1,625	1,000
Advance for future increase of invested capital	-	(17,226)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	(12,116)	(42,485)
CASH FLOW FROM FINANCING ACTIVITIES		
Dividends paid	(146)	-
Interest on capital paid	(19,580)	-
Share repurchased	-	-
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	(19,726)	-
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	187,778	117,981
Cash, Cash Equivalents and short-term investments		
Balance at the beginning of period	992,149	795,231
Balance at the end of period	1,179,927	913,212
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	187,778	117,981


Net cash, zero debt

R\$ million



Cash flow 1Q24

R\$ million



Performance comment

CAPEX


The IT development has historically been Odontoprev's largest investment item.

R\$ 000	1Q24	1Q23	Δ %
IT platform, acquisition/license of software	13,344	24,954	(46.5)
Computer equipment	99	557	(82.2)
Dental plan equipment, furniture and utensils	46	1,012	(95.4)
Installations	250	97	158.8
Others	3	488	(99.3)
Total CAPEX	13,743	27,106	(49.3)

The annual CAPEX level reflects investments in the company's digital initiatives, maturing in 2023 and 2024. In the last twelve months, investments in technology are already down to R\$80,762.

CAPEX: Technology represents the main investment

R\$ million



¹ IT platform, acquisition/licence of software and computer equipment

Performance comment

Shareholder remuneration

Dividends (DIV), interest on capital (IOC) and capital reduction (CR) - R\$ thousand													
Payment	Approval	Shareholder position	Type	Period	Gross amount R\$	Net amount R\$	Net value per share R\$				Annual total gross amount R\$	Net Income	Payout
							DIV	IOC	CR	Total			
Total paid in 2014:					216,658	211,822	0.347440879	0.051619184	-	0.399060063	213,582	194,709	110%
Total paid in 2015:					223,205	217,921	0.356336989	0.056787711	-	0.413124700	220,945	220,946	100%
Total paid in 2016:					185,559	178,759	0.265208801	0.072859879	-	0.338068680	172,791	215,990	80%
Total paid in 2017:					279,012	271,887	0.436065493	0.076050963	-	0.512116456	246,668	244,571 ¹	101%
Total paid in 2018:					86,716	78,340	0.058430479	0.089647129	-	0.148077608	173,357	284,793	61% ²
Total paid in 2019:					250,712	241,097	0.351910051	0.095206558	-	0.447116609	199,334	284,762	70%
Total paid in 2020:					270,219	262,006	0.406237632	0.087765775	-	0.494003407	333,213	361,128	92%
01/04/2021	12/10/2020	12/15/2020	IOC	4Q20	12,460	10,591	-	0.019968076	-	0.019968076	188,506	380,357	50% ³
04/06/2021	03/11/2021	03/16/2021	IOC	1Q21	12,980	11,033	-	0.020801634	-	0.020801634			
07/06/2021	04/05/2021	04/12/2021	DIV	4Q20	100,713	100,713	0.190396073	-	-	0.190396073			
07/06/2021	04/28/2021	05/19/2021	DIV	1Q21	95,754	95,754	0.181665407	-	-	0.181665407			
07/06/2021	06/11/2021	06/16/2021	IOC	2Q21	13,500	11,475	-	0.021851237	-	0.021851237			
10/06/2021	09/13/2021	09/22/2021	IOC	3Q21	13,481	11,459	-	0.022014029	-	0.022014029			
12/30/2021	12/14/2021	12/17/2021	IOC	4Q21	12,271	10,430	-	0.020127108	-	0.020127108			
Total paid in 2021:					261,159	251,455	0.372061480	0.104762084	-	0.476823564			
07/06/2022	03/21/2022	03/24/2022	IOC	1Q22	16,359	13,905	-	0.027130620	-	0.027130620	249,258	452,171	55% ⁴
10/05/2022	04/04/2022	04/04/2022	DIV	4Q21	40,520	40,520	0.071872189	-	-	0.071872189			
10/05/2022	04/27/2022	05/06/2022	DIV	1Q22	60,000	60,000	0.107203568	-	-	0.107203568			
12/21/2022	06/20/2022	06/23/2022	IOC	2Q22	17,633	14,988	-	0.026932989	-	0.026932989			
12/27/2022	09/15/2022	09/20/2022	IOC	3Q22	17,534	14,904	-	0.026933866	-	0.026933866			
12/27/2022	12/12/2022	12/15/2022	IOC	4Q22	17,732	15,072	-	0.027279708	-	0.027279708			
Total paid in 2022:					169,778	159,389	0.179075757	0.108277182	-	0.287352939			
07/12/2023	04/05/2023	04/20/2023	DIV	4Q22	120,000	120,000	0.217196275	-	-	0.217196275	509,728	536,554	95%
12/19/2023	03/14/2023	03/17/2023	IOC	1Q23	21,239	18,053	-	0.032675339	-	0.032675339			
12/19/2023	06/26/2023	06/29/2023	IOC	2Q23	21,111	17,944	-	0.032478425	-	0.032478425			
12/19/2023	09/19/2023	09/22/2023	IOC	3Q23	20,544	17,462	-	0.031606078	-	0.031606078			
Total paid in 2023:					182,894	173,460	0.217196275	0.096759842	-	0.313956117			
02/16/2024	12/13/2023	12/18/2023	IOC	4Q23	19,580	16,643	-	0.030122765	-	0.030122765	509,728	536,554	95%
Total paid in 2024:					19,580	16,643	-	0.030122765	-	0.030122765			
08/21/2024	04/03/2024	04/12/2024	DIV	4Q23	200,000	200,000	0.364065058	-	-	0.364065058	509,728	536,554	95%
12/18/2024	04/03/2024	04/12/2024	DIV	4Q23	227,254	227,254	0.413675305	-	-	0.413675305			
08/21/2024	03/27/2024	04/01/2024	IOC	1Q24	22,779	19,362	-	0.035162942	-	0.035162942			
12/18/2024	05/07/2024	05/15/2024	DIV	1Q24	73,000	73,000	0.133046690	-	-	0.133046690			
Total to be paid in 2024:					523,033	519,616	0.910787053	0.035162942	-	0.945949995			
Total since the IPO					3,730,478	3,619,129							

¹ Net income does not consider INSS Bradesco Dental and Odontoprev;

² Acquisition of Odonto System on 08/07/2018;

³ In 2021, there was, in additional, R\$177 million disbursed in Buyback Program, raising the payout to 96%;

⁴ In 2022, there was, in additional, R\$163 million disbursed in Buyback Program, raising the payout to 91%.

Performance comment

Share Buyback Program

In addition to regular payments of cash dividends, the company also carries out Share Buyback Programs in order to maximize the creation of value for shareholders.

At a meeting held on February 28th, 2024, the Board of Directors approved a new Buyback Program, up to 10 million shares, representing 3.9% of free float, up to 18 months, until August 2025.


As per April 30th, 2024, the total number of treasury shares acquired reached 3,816,100, with an average nominal cost of R\$11.64 per share.

The table below demonstrates the execution of the Share Buyback Program:

Share Buyback Program (accrual basis)			
Date	# shares	Amount (R\$)	Nominal cost per share (R\$)
March	1,854,600	22,179,058	11.96
April	1,961,500	22,256,263	11.35
2024	3,816,100	44,435,321	11.64

In a meeting held on May 7th, 2024, the Board of Directors approved the distribution of dividends for 1Q24 of R\$73 million, which added to the interest on capital of R\$23 million and the share buyback of R\$44 million up to April, totaled R\$140 million, 90% of the R\$155 million 1Q24 net income.

Total shareholder remuneration since 2020: Dividends + IOC + Share buybacks




Performance comment

Capital Markets

The total return to shareholders was 4.6% in 1Q24, compared to -4.3% for the IBrX, with average annual growth of 13% since the IPO, versus a CAGR of 8% for the IBrX.


Odontoprev total shareholder return since IPO x IBrX



The market cap reached R\$6.7 billion in MAR24, higher than the 2023 level.

Market Cap since IPO

R\$ billion




Performance comment

In 2023, the ADTV was R\$25 million, 69% higher than 4Q23.

Improving liquidity of shares

R\$ million




The number of individual investors was 42,775, down 16.7% YoY.

Odontoprev in Capital Markets	1Q24	1Q23	Δ %
Total number of shareholders	43,289	51,860	(16.5)
Individual investors	42,775	51,333	(16.7)
Institutional investors	514	527	(2.5)
Shares (thousand)	552,496	568,466	(2.8)
Treasury shares	1,855	15,970	(88.4)
Share price (R\$)	12.16	11.00	10.5
Market Cap (R\$ million)	6,718	6,253	7.4

Performance comment

Global shareholder structure: investors from more than 30 countries

APR/24



Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

1. Operations and general information

Odontoprev S.A. (Company or Odontoprev) is a publicly-held corporation located at Alameda Araguaia, 2104, 21º andar, Alphaville – Barueri, São Paulo – Brazil.

The Company started operating on August 28, 1987 and is engaged in providing private dental care plans, the management, sale or availability of these plans to corporations and/or individuals, as well holding interests, as partner, shareholder or unitholder in other civil or commercial companies, in commercial enterprises of any nature, in Brazil and/or overseas, and the management of its own assets and/or those of third parties.

The Company is classified as a dental operator in the tertiary sector, according to Normative Resolution (RN) 531 of May 02, 2022 of the National Agency of Supplementary Health (ANS).

The Odontoprev’s shares are traded on B3 under the ticker “ODPV3” and has been listed in the corporate governance segment called Novo Mercado (New Market) since December 01, 2006.

On March 31, 2024, the Company declares that it is able to take to maturity the interest earning bank deposits classified in the “amortized cost” category.

The Company holds direct and indirect interests in the following companies:

	Interest in capital (%)							
	March 31, 2024				December 31, 2023			
	Subsidiaries		Indirect associated company	Joint control	Subsidiaries		Indirect associated company	Joint control
Direct	Indirect	Direct			Indirect			
COMPANIES:								
Odontoprev Serviços Ltda. (Odontoprev Serviços)	100.0	-	-	-	100.0	-	-	-
Easy Software S.A. (Easy Software)	-	51.0	-	-	-	51.0	-	-
Dental Partner Comércio de Produtos e Equipamentos Odontológicos Ltda. (Dental Partner)	-	100.0	-	-	-	100.0	-	-
SF 210 Participações Societárias S.A. (SF 210)	-	-	18.1	-	-	-	18.1	-
Clidec Participações S.A. (Clidec Participações)	-	100.0	-	-	-	100.0	-	-
Machiron Desenvolvimento de Sistemas S.A. (MaChiron)	-	-	20.0	-	-	-	20.0	-
TERTIARY SEGMENT DENTAL OPERATOR – RN 531 ANS:								
Brasilidental Operadora de Planos Odontológicos S.A. (Brasilidental)	-	-	-	25.0	-	-	-	25.0
NETWORK OF DENTAL AND RADIOLOGICAL CLINICS:								
Clidec - Clínica Dentária Especializada Cura D'ars Ltda. (Clidec)	100.0	-	-	-	100.0	-	-	-
Boutique Dental Ltda. (Boutique Dental)	-	100.0	-	-	-	100.0	-	-
Clínicas Radiológicas Papaiz (Papaiz) ¹	-	100.0	-	-	-	100.0	-	-
Lúmax Radiologia e Tomografia Odontológica Ltda (Lúmax) ¹	-	100.0	-	-	-	100.0	-	-
COMPANIES IN MEXICO:								
Odontored CV Sociedad Anónima de Capital Variable (Odontored)	100.0	-	-	-	100.0	-	-	-
Oprev Administradora Sociedad Anónima de Capital Variable (Oprev)	-	100.0	-	-	-	100.0	-	-

¹ Subsidiary acquired by Clidec Participações as of February 1, 2023.

Approval of condensed interim financial statements

The authorization and approval to issue these individual and consolidated, condensed interim financial statements were given by the Board of Directors (BD) in a meeting held on May 07, 2024.

2. Description of material accounting policies

2.1. Preparation basis

The Company's individual interim condensed financial statements were prepared in accordance with technical pronouncement CPC 21 (R1) – “Interim Financial Reporting”, and the interim condensed financial statements were prepared in accordance with technical pronouncement CPC 21 (R1) – “Interim Financial Reporting”, equivalent to IAS 34, issued by the International Accounting Standards Board (IASB), according to the going concern assumption. Moreover, all relevant information specific to the financial statements, and only such information, is being evidenced, and corresponds to the information used by the Management in Company's administration.

The individual, consolidated and condensed interim financial statements were prepared and are being presented in accordance with the requirements of the Brazilian Securities and Exchange Commission (CVM).

According to CVM/SNC/SEP Circular Letter 003/2011, this quarterly information is presented in line with the concept of selected explanatory notes without repeating certain explanatory notes previously disclosed, but with an indication of the changes that occurred in the period and, therefore, must be read together with the annual financial statements for the year ended December 31, 2023, disclosed to the CVM on February 28, 2024.

2.2. Standards and interpretations

CVM Resolution 193/2023

The CVM published on October 20, 2023, effective as of November 1, 2023, Resolution CVM 193, which allows publicly-held companies to voluntarily prepare and disclose a sustainability-related financial information report based on the international standard (IFRS S1 and S2) issued by the International Sustainability Standards Board (ISSB). The adoption of this new standard will be mandatory for publicly-held companies starting from years beginning on or after January 01, 2026. The Company started the studies for implementation to meet the requirements of the new standard, according to the regulatory deadline. At this time, the Company's Management has chosen not to make this voluntary disclosure.

Constitutional amendment 132 of December 20, 2023

On December 20, 2023, Constitutional Amendment 132 was enacted, laying the foundations for Tax Reform. The main effect of the approval is the unification, as of 2033, of five taxes - ICMS, ISS, IPI, PIS and Cofins - into a single levy, which will be divided between the federal levels (CBS: Contribution on Goods and Services) and state/municipal (IBS: Tax on sales and services). The approved text needs to be regulated through the issue of Complementary Laws, which will be evaluated by the Management when they are published by the Brazilian Federal Revenue Service.

IFRS 18/2024

The International Accounting Standards Board (IASB) issued IFRS 18 - Presentation and Disclosure in Financial Statements on April 09, 2024. This standard includes requirements for all entities applying IFRS for the presentation and disclosure of information in financial statements and will replace IAS 1 - Presentation of Financial Statements,

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

being applicable to an annual reporting period beginning on or after January 01, 2027. The Company has not yet carried out an assessment of the impacts.

3. Interest earning bank deposits (financial assets at fair value through profit or loss and amortized cost)

	Rating	Company		Consolidated	
		March 31, 2024	December 31, 2023	March 31, 2024	December 31, 2023
Fixed income investment fund	Current assets	347,892	180,916	367,312	199,104
CETES	Current assets	-	-	9,186	9,800
Fair value through profit or loss		347,892	180,916	376,497	208,904
NTN-B	Current assets	137,760	137,884	137,760	137,884
LTN	Current assets	11,160	10,845	11,160	10,845
NTN-B.	Non-current assets	491,974	466,775	491,974	466,775
NTN-F.	Non-current assets	149,684	153,350	149,684	153,350
Amortized cost		790,578	768,855	790,578	768,855
		1,138,470	949,771	1,167,075	977,758
	Current assets	496,812	329,646	525,417	357,633
	Non-current assets	641,658	620,125	641,658	620,125
		1,138,470	949,771	1,167,075	977,758

Investment funds (fixed income inv. fund): investment fund units on BRAM FI RF Crédito Privado Bancos and BRAM FI Renda Fixa Referenciado DI, which are valued based on the values disclosed by Bradesco Asset Management.

Certificados de la Tesorería de la Federación (CETES): fixed-income public bonds held by Odontored issued by the Mexican government.

National Treasury Notes - Series B (NTN-B) - Treasury IPCA with twice-yearly interest: federal public bonds, refer to the assets from managed portfolios, which are managed by Bradesco Asset Management. As of March 31, 2024, the fair value is R\$ 595,489 (R\$ 596,507 as of December 31, 2023).

National Treasury Notes - Series F (NTN-F) - Fixed rate Treasury with twice-yearly interest: federal public bonds, refer to the assets from managed portfolios, which are managed by Bradesco Asset Management. As of March 31, 2024, the fair value is R\$ 146,913 (R\$ 152,851 as of December 31, 2023).

National Treasury Bills (LTN) - Fixed rate Treasury: federal public bonds, refer to the assets from managed portfolios, which are managed by Bradesco Asset Management. As of March 31, 2024, the fair value is R\$ 11,222 (R\$ 10,937 as of December 31, 2023).

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

Investment portfolio per original maturities - Company

	Rating	Without maturity	181-360 days	>360 days	Total
Fixed income investment fund	Current assets	347,892	-	-	347,892
Fair value through profit or loss		347,892	-	-	347,892
NTN-B	Current assets	-	137,760	-	137,760
LTN	Current assets	-	11,160	-	11,160
NTN-B	Non-current assets	-	-	491,974	491,974
NTN-F	Non-current assets	-	-	149,684	149,684
Amortized cost		-	148,920	641,658	790,578
March 31, 2024		347,892	148,920	641,658	1,138,470
December 31, 2023		180,916	148,730	620,150	949,771

Investment portfolio per original maturities - Consolidated

	Rating	Without maturity	01-180 days	181-360 days	>360 days	Total
Fixed income investment fund	Current assets	367,312	-	-	-	367,312
CETES	Current assets	-	9,186	-	-	9,186
Fair value through profit or loss		367,312	9,186	-	-	376,497
NTN-B	Current assets	-	-	137,760	-	137,760
LTN	Current assets	-	-	11,160	-	11,160
NTN-B	Non-current assets	-	-	-	491,974	491,974
NTN-F	Non-current assets	-	-	-	149,684	149,684
Amortized cost		-	-	148,920	641,658	790,578
March 31, 2024		367,312	9,186	148,920	641,658	1,167,075
December 31, 2023		199,104	9,799	148,730	620,125	977,758

Changes in investment portfolio - Company

	Fair value through profit or loss		Amortized cost				
	Fixed income inv. fund	Total	NTN-B1	NTN-F1	LTN1	Total	Total
December 31, 2022	104,614	104,614	471,331	124,384	48,087	643,802	748,416
Investments	1,101,969	1,101,969	156,980	27,996	-	184,976	1,286,945
(-) Redemptions	(1,045,431)	(1,045,431)	(72,325)	(12,365)	(40,863)	(125,553)	(1,170,984)
Earnings	19,764	19,764	48,674	13,335	3,621	65,630	85,394
December 31, 2023	180,916	180,916	604,660	153,350	10,845	768,855	949,771
Investments	338,546	338,546	19,997	-	-	19,997	358,543
(-) Redemptions	(179,602)	(179,602)	(11,720)	(7,119)	-	(18,839)	(198,441)
Earnings	8,032	8,032	16,797	3,453	315	20,565	28,597
March 31, 2024	347,892	347,892	629,734	149,684	11,160	790,578	1,138,470

¹Redemptions corresponding to receipt of interest coupon

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

Changes in investment portfolio - Consolidated

	Fair value through profit or loss			Amortized cost				
	Fixed income inv. fund	CETES	Total	NTN-B1	NTN-F1	LTN1	Total	Total
	December 31, 2022	127,381	8,211	135,592	471,331	124,384	48,087	643,802
Investments	1,199,648	92,585	1,292,233	156,980	27,996	-	184,976	1,477,209
(-) Redemptions	(1,151,915)	(91,964)	(1,243,879)	(72,325)	(12,365)	(40,863)	(125,553)	(1,369,432)
Earnings	23,990	967	24,957	48,674	13,335	3,621	65,630	90,587
December 31, 2023	199,104	9,799	208,903	604,660	153,350	10,845	768,855	977,758
Investments	363,686	23,482	387,168	19,997	-	-	19,997	407,165
(-) Redemptions	(204,116)	(24,344)	(228,460)	(11,720)	(7,119)	-	(18,839)	(247,299)
Earnings	8,638	248	8,886	16,797	3,453	315	20,565	29,451
March 31, 2024	367,312	9,185	376,497	629,734	149,684	11,160	790,578	1,167,075

¹Redemptions corresponding to receipt of interest coupon.

4. Insurance contract assets

Changes in insurance contract assets are highlighted below:

	<u>Company</u>	<u>Consolidated</u>
Balance at December 31, 2022	31,256	36,003
Consideration not assigned	(1,573,633)	(1,457,528)
Considerations attributed to the PAA period	1,573,502	1,454,437
Balance at December 31, 2023	31,125	32,912
Consideration not assigned	(402,761)	(409,632)
Considerations attributed to the PAA period	409,733	422,880
Balance at March 31, 2024	38,097	46,160

5. Tax and social security credits

	<u>Company</u>		<u>Consolidated</u>	
	March 31, 2024	December 31, 2023	March 31, 2024	December 31, 2023
INSS	5,601	143	5,601	143
IRPJ	20,766	22,499	23,612	25,311
CSLL	3,719	4,425	5,917	6,612
IRRF	55	55	1,133	1,112
PIS and COFINS	133	131	1,491	1,707
ISS	1,529	1,499	1,545	1,516
Other	-	-	750	708
	31,803	28,752	40,050	37,109
Current assets	7,318	4,794	15,337	12,922
Non-current assets	24,485	23,958	24,713	24,187
	31,803	28,752	40,050	37,109

Corporate income tax (IRPJ) and social contribution (CSLL): corporate income tax (IRPJ) balance composed of advances from the current and previous years, and social contribution (CSLL) balance composed of credits from previous years, both arising from technological innovation, subject to approval by the MCTI (Ministry of Science, Technology and Innovation).

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

INSS: Odontoprev (which merged Rede Dental) received a final and unappealable decision in the lawsuit, securing its right to offset social security contributions unduly collected by Rede Dental on payments made to individual dentists between October 2007 to October 2019 (period after acquisition by Odontoprev).

6. Other accounts receivable

	Company		Consolidated	
	March 31, 2024	December 31, 2023	March 31, 2024	December 31, 2023
Advances to suppliers and others	40	127	857	839
Advances to employees	8,932	9,095	10,102	10,485
Recoverable TSS ¹	-	45,934	-	45,934
Other credits receivable	13,226	12,640	31,000	29,416
	22,198	67,796	41,959	86,674

¹In August 2023, there was recognition of the recovery of amounts paid in the supplementary health fee - TSS. This recognition occurred due to the inclusion in the list of court-ordered debt payments (precatórios), involving Odontoprev's cases. In January 2024, the Company became aware of the judicial deposit made by the Federal Government, and in February, the amount of R\$ 46,052 was transferred to the Company's bank account.

7. Non-current receivables

7.1. Income tax e Social contribution Deferred assets

	Rating	Realization estimate	Note	Company				Consolidated				
				December 31, 2023	Formation	Realized	March 31, 2024	December 31, 2023	Formation	Realized	March 31, 2024	
Timing differences												
Provision for lawsuits (contingencies) ¹	Assets	>12 months	14.1	11,520	743	-	12,263	12,271	777	-	-	13,048
Sundry provisions	Assets	≤12 months	13	4,075	-	(910)	3,165	3,839	-	(915)	-	2,924
Long-term incentive program (ILP)	Assets	≤12 months and >12 months	-	7,977	1,608	-	9,585	13,708	1,731	-	-	15,439
Profit sharing	Assets	≤12 months	-	5,418	1,874	-	7,292	9,165	2,153	-	-	11,318
CPC 50/IFRS 17 effect	Assets	≤12 months	-	29,926	7,198	(156)	36,968	30,928	7,198	(540)	-	37,586
Other	Assets	≤12 months	-	5,126	-	(765)	4,361	561	-	(463)	-	98
Deferred IRPJ/CSLL (Assets)				64,042	11,423	(1,831)	73,634	70,472	11,859	(1,918)	-	80,413
Amortization of goodwill	Liabilities	>12 months	-	(55,280)	(442)	-	(55,722)	(55,275)	(442)	-	-	(55,717)
Other	Liabilities	>12 months	-	-	-	-	-	(5)	-	-	-	(5)
Deferred IRPJ/CSLL (Liabilities)				(55,280)	(442)	-	(55,722)	(55,280)	(442)	-	-	(55,722)
Deferred IRPJ/CSLL				8,762	10,981	(1,831)	17,912	15,192	11,417	(1,918)	-	24,691
Deferred income tax (IRPJ)				6,443	8,075	(1,346)	13,172	11,394	8,395	(1,512)	-	18,277
Deferred social contribution (CSLL)				2,319	2,906	(485)	4,740	3,798	3,022	(406)	-	6,414
Deferred IRPJ/CSLL				8,762	10,981	(1,831)	17,912	15,192	11,417	(1,918)	-	24,691

7.2. Judicial deposits

	Company		Consolidated	
	March 31, 2024	December 31, 2023	March 31, 2024	December 31, 2023
Tax	28,280	27,405	29,474	28,597
ISS ¹	26,715	25,866	26,715	25,866
Other	1,565	1,539	2,759	2,731
Social security and labor	307	265	407	351
Civil	1,709	1,533	1,709	1,533
	30,297	29,203	31,590	30,481

¹From the merged company Odonto System, the full amount of the Service Tax - ISS was deposited in court without deducting the events from the calculation basis (objects of the lawsuit). Amount fully provisioned in non-current liabilities under "Tax obligations".

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

8. Investments

	Company						
	Interest in subsidiaries			Jointly-controlled subsidiary	Other investments	Total investments	
	Odontored	Clidec	Odontoprev Serviços	Total	Brasildental		
December 31, 2023	9,693	45,390	20,996	76,079	4,469	2	80,550
Dividends	-	-	(3,000)	(3,000)	(1,625)	-	(4,625)
Revenue/(expense) in equity in net income of subsidiaries	2,157	(428)	3,034	4,763	1,085	-	5,848
Other comprehensive income	521	-	6	527	-	-	527
Other comprehensive income (CPC 50/IFRS 17)	51	-	-	51	(68)	-	(17)
March 31, 2024	12,422	44,962	21,036	78,420	3,861	2	82,283
Capital	6,030	31,516	9,700	-	9,500	-	-
Units/Shares	6,030	31,516	9,700	-	380,000	-	-
Interest (%)	100.0	100.0	100.0	-	25.0	-	-
Total assets	16,624	50,672	36,084	-	31,594	-	-
Liabilities	14,467	51,100	33,050	-	27,255	-	-
Shareholders' equity	10,101	44,962	21,037	-	15,441	-	-
Net revenue	13,147	8,367	14,366	-	24,744	-	-
Costs and expenditures	10,990	7,940	11,332	-	17,988	-	-
Taxes and interests	-	855	-	-	2,417	-	-
Income (loss) for the year	2,157	(428)	3,034	-	4,339	-	-

	Consolidated					
	Interest in associated companies			Jointly-controlled subsidiary	Other investments	Total investments
	Other companies			(regulated entity)		
	Machiron	SF 210	Total	Brasildental		
December 31, 2023	148	1,677	1,825	4,469	56	6,350
Dividends	-	-	-	(1,625)	-	(1,625)
Revenue/(expense) in equity in net income of subsidiaries	(17)	(12)	(29)	1,085	-	1,056
Other comprehensive income (CPC 50/IFRS 17)	-	-	-	(68)	-	(68)
March 31, 2024	131	1,665	1,796	3,861	56	5,713
Capital	595	8,859	-	9,500	-	-
Units/Shares	595	8,859	-	380,000	-	-
Interest (%)	20	18	-	25	-	-
Total assets	677	9,193	-	31,594	-	-
Liabilities	755	9,222	-	27,254	-	-
Shareholders' equity	600	9,190	-	15,441	-	-
Net revenue	197	-	-	24,744	-	-
Costs and expenditures	284	67	-	17,988	-	-
Taxes and interests	-	-	-	2,417	-	-
Income (loss) for the period	(87)	(67)	-	4,339	-	-

9. Property, plant and equipment

	Changes in property, plant and equipment - Company								
	December 31, 2023	Acquisitions	Write-offs	Depreciation / Amortization	March 31, 2024	Cost of acquisition	Depreciation / Amortization	Book balance, net	Annual depreciation rate (%)
IT equipment	8,304	-	-	(755)	7,549	31,254	(23,705)	7,549	20
Vehicles	1,003	-	-	(83)	920	1,719	(799)	920	20
Facilities	326	-	-	(10)	316	507	(191)	316	10
Machinery and Equip.	481	-	-	(17)	464	1,821	(1,357)	464	10
Furniture and fixtures	592	-	-	(40)	552	3,305	(2,753)	552	10
Communication equipment	120	-	-	(4)	116	743	(627)	116	10
Dental equipment	73	-	-	(4)	69	519	(450)	69	10
Property, plant and equipment for use	10,899	-	-	(913)	9,986	39,868	(29,882)	9,986	
Other fixed assets	4,362	135	-	(424)	4,073	15,760	(11,687)	4,073	20
Property, plant and equipment	15,261	135	-	(1,337)	14,059	55,628	(41,569)	14,059	
Right-of-use (CPC 6 (R2)/IFRS 16) ⁱ	12,372	-	-	(460)	11,912	16,822	(4,910)	11,912	
Property, plant and equipment	27,633	135	-	(1,797)	25,971	72,450	(46,479)	25,971	

ⁱ Depreciation calculated according to the duration of the real estate and machinery and equipment lease contract.

	Changes in Property, Plant and Equipment - Consolidated								
	December 31, 2023	Acquisitions	Write-offs	Depreciation / Amortization	March 31, 2024	Cost of acquisition	Depreciation / Amortization	Book balance, net	Annual depreciation rate (%)
IT equipment	8,800	99	-	(830)	8,069	33,617	(25,548)	8,069	20
Vehicles	986	-	-	(95)	891	1,870	(979)	891	20
Facilities	513	-	-	(15)	498	844	(346)	498	10
Machinery and Equip.	7,129	24	(6)	(383)	6,764	14,188	(7,424)	6,764	10
Furniture and fixtures	1,602	6	(39)	(87)	1,482	5,147	(3,665)	1,482	10
Communication equipment	124	3	-	(5)	122	768	(646)	122	10
Dental equipment	1,645	15	-	(65)	1,595	4,157	(2,562)	1,595	10
Total for own use	20,799	147	(45)	(1,480)	19,421	60,591	(41,170)	19,421	
Other property, plant, and equipment (improvements)	7,678	250	-	(659)	7,269	26,910	(19,641)	7,269	20
Total other property, plant and equipment	28,477	397	(45)	(2,139)	26,690	87,501	(60,811)	26,690	
Right-of-use (CPC 06 (R2)/IFRS 16) ⁱ	26,583	52	(122)	(1,510)	25,003	39,580	(14,577)	25,003	-
Total property, plant and equipment	55,060	449	(167)	(3,649)	51,693	127,081	(75,388)	51,693	

ⁱ Depreciation calculated according to the duration of the real estate and machinery and equipment lease contract.

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

10. Intangible assets

10.1. Goodwill on the acquisition of investments

Cash generating unit (CGU)	March 31, 2024	December 31, 2023
	Net goodwill	Net goodwill
Odontoprev ¹	99,515	99,515
Bradesco Dental ²	409,640	409,640
Odonto System ³	145,793	145,793
Company	654,948	654,948
Various units, with non-significant goodwill ⁴	14,521	14,521
Consolidated	669,469	669,469

¹ It refers to a grouping of cash-generating units from businesses acquired over time with the aim of regional expansion, products and strengthening the brand.

² Integration of the activities carried out, complementing skills and creating a differentiated operation in the market.

³ Objective of regional expansion and products.

⁴ Acquisitions of businesses with the aim of verticalizing the operation.

The Company evaluates its recoverability through impairment tests and for goodwill from acquisitions of investments allocated to cash generating units (CGUs).

As of March 31, 2024, through internal assessments, Management concluded that there was no evidence of impairment.

The last impairment test was performed on November 30, 2023 and is carried out annually by the Company.

	Company				Consolidated			
	Goodwill on acquisition of investments	Development of systems and software use licenses	Allocated intangible assets	Intangible assets	Goodwill on acquisition of investments	Development of systems and software use licenses	Allocated intangible assets	Intangible assets
December 31, 2023	654,948	178,067	23,728	856,743	669,469	180,547	29,636	879,652
Additions	-	13,327	-	13,327	-	13,344	-	13,344
Write-offs	-	(279)	-	(279)	-	(279)	-	(279)
Amortizations	-	(8,497)	(1,758)	(10,255)	-	(8,681)	(1,858)	(10,539)
March 31, 2024	654,948	182,618	21,970	859,536	669,469	184,931	27,778	882,178
Cost	669,822	324,715	69,514	1,064,051	684,608	332,191	75,842	1,092,641
Accumulated amortizations	(14,874)	(142,097)	(47,544)	(204,515)	(15,139)	(147,260)	(48,064)	(210,463)
Book balance, net	654,948	182,618	21,970	859,536	669,469	184,931	27,778	882,178

10.2. Intangible assets

11. Liabilities from insurance and reinsurance contracts

Pursuant to CPC 50/IFRS 17, we highlight below the breakdown and changes of liabilities from insurance and reinsurance contracts:

(a) Liabilities from insurance and reinsurance contracts

	Company		Consolidated	
	March 31, 2024	December 31, 2023	March 31, 2024	December 31, 2023
Liabilities for Remaining Coverage (BBA)	117,543	111,822	117,543	111,822
Liabilities claims incurred	176,075	164,102	178,221	165,739
	293,618	275,924	295,764	277,561

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

(b) Remaining coverage for the general model (Building Block Approach - BBA)

	Company and Consolidated					
	Subscribed contracts	Acquired contracts	Total	Subscribed contracts	Acquired contracts	Total
	Non-Onerous Contracts			Non-Onerous Contracts		
	Period ended March 31, 2024			Period ended December 31, 2023		
Cash flows from acquisition	60,315	2,954,129	3,014,444	63,810	2,864,721	2,928,531
Events and other directly attributable expenses	176,363	13,435,944	13,612,307	212,273	12,976,170	13,188,443
Estimates of present value of future cash outflow	236,678	16,390,073	16,626,751	276,083	15,840,891	16,116,974
Estimates of present value of future cash inflow	(351,908)	(16,862,962)	(17,214,870)	(370,672)	(16,414,520)	(16,785,192)
Risk adjustment for non-financial risk adjustment	2,925	11,253	14,178	2,527	12,571	15,098
Contractual service margin (CSM)	111,973	579,511	691,484	94,510	670,432	764,942
Net amount included in the provision of insurance contracts	(332)	117,875	117,543	2,448	109,374	111,822

(c) Realization of insurance coverage margin

	Company and Consolidated						
	Period ended March 31, 2024						
	≤01 year	01-02 years	02-03 years	03-04 years	04-05 years	>05 years	Total
Direct Insurance	186,991	132,537	97,806	75,504	58,962	139,684	691,484
Insurance contracts issued	186,991	132,537	97,806	75,504	58,962	139,684	691,484

	Company and Consolidated						
	Period ended December 31, 2023						
	≤01 year	01-02 years	02-03 years	03-04 years	04-05 years	>05 years	Total
Direct Insurance	167,505	150,522	111,377	86,264	67,830	181,444	764,942
Insurance contracts issued	167,505	150,522	111,377	86,264	67,830	181,444	764,942

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

(d) Changes in reserves - remaining coverage and claims incurred

	Company					
	Liability for remaining coverage	Liabilities claims incurred - BBA		Liabilities claims incurred - PAA		Total
		Best outflow estimate (BEL)	Risk adjustment (RA)	Best outflow estimate (BEL)	Risk adjustment (RA)	
Balance at December 31, 2022	148,980	32,007	901	131,144	3,758	316,790
Contracts by the total retrospective method	(260,056)	-	-	-	-	(260,056)
Contracts by the fair value method	(224,550)	-	-	-	-	(224,550)
Insurance revenues	(484,606)	-	-	-	-	(484,606)
Incurring claims and other insurance service expenses	-	292,883	8,790	1,475,327	47,024	1,824,024
Adjustments regarding the past to incurred claim liabilities	-	(223,787)	(8,408)	(807,782)	(42,499)	(1,082,476)
Amortization of cash flows from insurance acquisition	112,464	-	-	-	-	112,464
Insurance service expenses	112,464	69,096	382	667,545	4,525	854,012
Income (loss) from insurance service	(372,142)	69,096	382	667,545	4,525	369,406
Net financial expenses for insurance contracts	31,529	2,070	101	-	-	33,700
Financial expenses	31,529	2,070	101	-	-	33,700
Total changes in the statement of comprehensive income (ORA)	(54,954)	248	5	-	-	(54,701)
Premiums received	493,136	-	-	-	-	493,136
Cash flow from acquisition	(87,572)	-	-	-	-	(87,572)
Claims paid	-	(84,225)	-	(663,455)	-	(747,680)
Cash flows	405,564	(84,225)	-	(663,455)	-	(342,116)
Experience adjustment	(47,155)	-	-	-	-	(47,155)
Balance at December 31, 2023	111,822	19,196	1,389	135,234	8,283	275,924
Contracts by the total retrospective method	(61,135)	-	-	-	-	(61,135)
Contracts by the fair value method	(60,238)	-	-	-	-	(60,238)
Insurance revenues	(121,373)	-	-	-	-	(121,373)
Incurring claims and other insurance service expenses	-	56,059	4,070	352,889	25,175	438,193
Adjustments regarding the past to incurred claim liabilities	-	(41,704)	(3,356)	(186,484)	(20,094)	(251,638)
Amortization of cash flows from insurance acquisition	21,185	-	-	-	-	21,185
Insurance service expenses	21,185	14,355	714	166,405	5,081	207,740
Income (loss) from insurance service	(100,188)	14,355	714	166,405	5,081	86,367
Net financial expenses for insurance contracts	7,962	441	49	-	-	8,452
Financial expenses	7,962	441	49	-	-	8,452
Total changes in the statement of comprehensive income (ORA)	6,972	57	5	-	-	7,034
Premiums received	127,926	-	-	-	-	127,926
Cash flow from acquisition	(23,124)	-	-	-	-	(23,124)
Claims paid	-	(16,418)	-	(158,716)	-	(175,134)
Cash flows	104,802	(16,418)	-	(158,716)	-	(70,332)
Experience adjustment	(13,827)	-	-	-	-	(13,827)
Balance at March 31, 2024	117,543	17,631	2,157	142,923	13,364	293,618

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

	Consolidated					
	Liability for remaining coverage	Liabilities claims incurred - BBA		Liabilities claims incurred - PAA		Total
		Best outflow estimate (BEL)	Risk adjustment (RA)	Best outflow estimate (BEL)	Risk adjustment (RA)	
Balance at December 31, 2022	148,980	32,007	901	132,544	3,767	318,199
Contracts by the total retrospective method	(260,056)	-	-	-	-	(260,056)
Contracts by the fair value method	(224,550)	-	-	-	-	(224,550)
Insurance revenues	(484,606)	-	-	-	-	(484,606)
Incurred claims and other insurance service expenses	-	292,883	8,790	1,425,657	46,233	1,773,563
Adjustments regarding the past to incurred claim liabilities	-	(223,787)	(8,408)	(757,897)	(41,695)	(1,031,787)
Amortization of cash flows from insurance acquisition	112,464	-	-	-	-	112,464
Insurance service expenses	112,464	69,096	382	667,760	4,538	854,240
Income (loss) from insurance service	(372,142)	69,096	382	667,760	4,538	369,634
Net financial expenses for insurance contracts	31,529	2,070	101	-	-	33,700
Financial expenses	31,529	2,070	101	-	-	33,700
Total changes in the statement of comprehensive income (ORA)	(54,954)	248	5	-	-	(54,701)
Premiums received	493,136	-	-	-	-	493,136
Cash flow from acquisition	(87,572)	-	-	-	-	(87,572)
Claims paid	-	(84,225)	-	(663,455)	-	(747,680)
Cash flows	405,564	(84,225)	-	(663,455)	-	(342,116)
Experience adjustment	(47,155)	-	-	-	-	(47,155)
Balance at December 31, 2023	111,822	19,196	1,389	136,849	8,305	277,561
Contracts by the total retrospective method	(61,135)	-	-	-	-	(61,135)
Contracts by the fair value method	(60,238)	-	-	-	-	(60,238)
Insurance revenues	(121,373)	-	-	-	-	(121,373)
Incurred claims and other insurance service expenses	-	56,059	4,070	373,875	25,259	459,263
Adjustments regarding the past to incurred claim liabilities	-	(41,704)	(3,356)	(206,947)	(20,192)	(272,199)
Amortization of cash flows from insurance acquisition	21,185	-	-	-	-	21,185
Insurance service expenses	21,185	14,355	714	166,927	5,068	208,249
Income (loss) from insurance service	(100,188)	14,355	714	166,927	5,068	86,876
Net financial expenses for insurance contracts	7,962	441	49	-	-	8,452
Financial expenses	7,962	441	49	-	-	8,452
Total changes in the statement of comprehensive income (ORA)	6,972	57	5	-	-	7,034
Premiums received	127,926	-	-	-	-	127,926
Cash flow from acquisition	(23,124)	-	-	-	-	(23,124)
Claims paid	-	(16,418)	-	(158,716)	-	(175,134)
Cash flows	104,802	(16,418)	-	(158,716)	-	(70,332)
Experience adjustment	(13,827)	-	-	-	-	(13,827)
Balance at March 31, 2024	117,543	17,631	2,157	145,060	13,373	295,764

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

(e) Contract measurement components - remaining coverage

	Company and Consolidated			
	Best outflow estimate (BEL)	Risk adjustment (RA)	Insurance coverage margin (CSM)	Total
Balance at December 31, 2022	(1,189,017)	17,788	1,320,209	148,980
CSM recognized for services provided	-	-	(221,762)	(221,762)
Changes in the risk adjustment recognized for expired risk	-	(5,220)	-	(5,220)
Experience adjustment	(257,624)	-	-	(257,624)
Changes regarding the current service	(257,624)	(5,220)	(221,762)	(484,606)
Changes in the CMS adjusting estimates	3,442,336	(49,606)	(3,439,885)	(47,155)
Changes in estimates that are not adjusted to the CSM	112,374	4	-	112,378
Contracts initially recognized in the period	(3,007,970)	48,912	2,959,058	-
Changes regarding the future service	546,740	(690)	(480,827)	65,223
Income (loss) from insurance service	289,116	(5,910)	(702,589)	(419,383)
Insurance contract financial expenses	(173,881)	3,220	147,322	(23,339)
Insurance contract financial expenses	(173,881)	3,220	147,322	(23,339)
Premiums received	493,136	-	-	493,136
Cash flows from acquisition of insurance	(87,572)	-	-	(87,572)
Cash flows	405,564	-	-	405,564
Balance at December 31, 2023	(668,218)	15,098	764,942	111,822
CSM recognized for services provided	-	-	(69,391)	(69,391)
Changes in the risk adjustment recognized for expired risk	-	(1,535)	-	(1,535)
Experience adjustment	(50,447)	-	-	(50,447)
Changes regarding the current service	(50,447)	(1,535)	(69,391)	(121,373)
Changes in the CMS adjusting estimates	261,017	(8,750)	(266,094)	(13,827)
Changes in estimates that are not adjusted to the CSM	21,200	-	-	21,200
Contracts initially recognized in the period	(253,907)	9,289	244,618	-
Changes regarding the future service	28,310	539	(21,476)	7,373
Income (loss) from insurance service	(22,137)	(996)	(90,867)	(114,000)
Insurance contract financial expenses	(2,566)	78	17,409	14,921
Insurance contract financial expenses	(2,566)	78	17,409	14,921
Premiums received	127,924	-	-	127,924
Cash flows from acquisition of insurance	(23,124)	-	-	(23,124)
Cash flows	104,800	-	-	104,800
Balance at March 31, 2024	(588,121)	14,180	691,484	117,543

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

(f) Insurance coverage margin

	Company and Consolidated		
	Contracts assessed through the fair value in the transition	Contracts assessed by the total retrospective method and new contracts	Total
CSM as of December 31, 2022	548,760	771,449	1,320,209
CSM recognized for services provided	(88,775)	(132,987)	(221,762)
Changes regarding the current service	(88,775)	(132,987)	(221,762)
Contracts initially recognized in the period	-	2,959,058	2,959,058
Changes in the CMS adjusting estimates	(78,731)	(3,361,154)	(3,439,885)
Changes regarding the future service	(78,731)	(402,096)	(480,827)
Income (loss) from insurance service	(167,506)	(535,083)	(702,589)
Insurance contract financial expenses	40,292	107,030	147,322
CSM as of December 31, 2023	421,546	343,396	764,942
CSM recognized for services provided	(32,979)	(36,412)	(69,391)
Changes regarding the current service	(32,979)	(36,412)	(69,391)
Contracts initially recognized in the period	-	244,618	244,618
Changes in the CMS adjusting estimates	(38,205)	(227,889)	(266,094)
Changes regarding the future service	(38,205)	16,729	(21,476)
Income (loss) from insurance service	(71,184)	(19,683)	(90,867)
Insurance contract financial expenses	9,029	8,380	17,409
CSM on March 31, 2024	359,391	332,093	691,484

12. Tax obligations

	Company		Consolidated	
	March 31, 2024	December 31, 2023	March 31, 2024	December 31, 2023
Income tax and social contribution payable¹	20,416	4,344	21,150	4,590
IRPJ	14,716	2,954	15,252	3,109
CSLL	5,700	1,390	5,898	1,481
Other federal tax liabilities	12,841	13,480	17,395	17,504
COFINS	5,308	4,637	5,637	5,078
PIS	863	754	934	849
PIS, COFINS and CSLL (PCC)	1,157	1,752	1,239	1,818
IRRF	5,508	6,328	5,736	6,752
IVA ²	-	-	3,423	2,560
Installment payment of taxes	-	-	408	420
Other	5	9	18	27
State tax liabilities	-	-	2	148
Municipal tax liabilities³	29,624	28,999	30,285	29,569
	62,881	46,823	68,832	51,811
Current liabilities	36,166	20,957	41,754	25,570
Non-current liabilities	26,715	25,866	27,078	26,241
	62,881	46,823	68,832	51,811

¹ The Company adopts the annual taxable income regime, paying the amount monthly based on the suspension and reduction balance sheets, through advance payment of taxes. This modality is directly related to the behavior of the income (loss) for the period (the year 2023 has ended and the year 2024 is still ongoing).

² Value Added Tax from Subsidiary Odontored.

³ It mainly refers to the service tax (ISS) payable from Odonto System.

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

13. Other accounts payable

	Company		Consolidated	
	March 31, 2024	December 31, 2023	March 31, 2024	December 31, 2023
Sundry provisions	9,194	11,774	9,279	11,880
Commissions	3,884	5,508	3,884	5,508
IT support and service	3,427	4,147	3,427	4,147
Telecom	110	245	110	245
Services	1,621	1,572	1,704	1,676
Marketing actions	152	302	154	304
Credits to be identified¹	10,032	9,505	10,208	9,776
Unearned revenue (CPC 47/IFRS 15)	-	-	2,654	2,433
Outros²	8,914	10,651	9,512	11,527
	28,140	31,930	31,653	35,616

¹ Correspond to amounts received from clients still unidentified.

² It refers mainly to revenues from post-payment contracts and cash consideration received in advance.

14. Non-current

14.1. Provision for tax, labor and civil lawsuits

	Company					December 31, 2023
	March 31, 2024					
	Tax	Civil		Social security and labor	Total	
Changes	Other	ANS1	Other			
Opening balance	598	27,422	4,634	1,230	33,884	34,036
Formation	-	2,031	3,885	57	5,973	26,719
Write-offs (payments/reversals)	(7)	(1,869)	(3,028)	(127)	(5,031)	(31,785)
Inflation adjustment	25	1,114	85	19	1,243	4,914
Provision	616	28,698	5,576	1,179	36,069	33,884

Number of lawsuits

995 830

¹ Those are Tax Assessment Notices drawn up by the ANS whose purpose is the non-payment of reimbursement for treatments performed at free choice by beneficiaries linked to certain products, mapped and monitored internally.

	Consolidated					December 31, 2023
	March 31, 2024					
	Tax	Civil		Social security and labor	Total	
Changes	Other	ANS1	Other			
Opening balance	1,917	27,422	4,634	2,993	36,966	35,404
Acquisition Balance Papaiz / Lúmax	-	-	-	-	-	1,045
Formation	-	2,031	3,888	346	6,265	29,010
Write-offs (payments/reversals)	(14)	(1,869)	(3,028)	(694)	(5,605)	(34,289)
Inflation adjustment	26	1,114	85	43	1,268	5,796
Provision	1,929	28,698	5,579	2,688	38,894	36,966

Number of lawsuits

1019 852

¹ Those are Tax Assessment Notices drawn up by the ANS whose purpose is the non-payment of reimbursement for treatments performed at free choice by beneficiaries linked to certain products, mapped and monitored internally.

As of March 31, 2024, the amounts related to possible losses not provided for in the Company and its Subsidiaries totaled (i) R\$ 3,410 - 71 labor lawsuits; (ii) R\$ 72,433 - 2,980 civil lawsuits; and (iii) R\$ 73,157 - 49 tax lawsuits (As of December 31, 2023, the amounts totaled (i) R\$ 2,791 - 45 labor lawsuits; (ii) R\$ 63,402 - 2,631 civil lawsuits; and (iii) R\$ 71,978 - 48 tax lawsuits).

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

14.2. Investments payable

According to Odonto System's purchase agreement, to secure the obligation to indemnify the sellers, the Company maintains a portion of the investment payable: (i) Odonto System - with settlement to be released; (ii) Mogidonto - with settlement in 6 installments adjusted by the CDI rate; and (iii) Lúmax - with settlement in 5 installments adjusted by the CDI rate.

	Company		Consolidated	
	March 31, 2024	December 31, 2023	March 31, 2024	December 31, 2023
Opening balance	8,645	20,719	9,271	20,727
(+) Acquisition of Lúmax by Papaiz ¹	-	-	-	493
(-) Payment - Odonto System	-	(10,159)	-	(10,159)
(+) Inflation adjustment	94	1,395	110	1,528
(-) Business combination - Mogidonto and Boutique	-	(1,188)	-	(1,188)
(-) Write-off of contingencies	-	(2,122)	-	(2,130)
	8,739	8,645	9,381	9,271
Current liabilities	5,176	5,082	5,305	5,208
Non-current liabilities	3,563	3,563	4,076	4,063
	8,739	8,645	9,381	9,271

¹ Indirect subsidiary acquired on February 01, 2023.

15. Right-of-use and lease liabilities – CPC 06 (R2) / IFRS 16

The Company and its subsidiaries recognized lease liabilities related to the rental of real estate properties in accordance with the assumptions in CPC 06 (R2)/IFRS 16 – Leases. These liabilities were measured considering the present value of future lease payments, discounted using the average rate of 10.57%, and the corresponding entry was recorded as right of use in assets. The total impacts measured are presented below:

	Rating	Company		Consolidated	
		March 31, 2024	December 31, 2023	March 31, 2024	December 31, 2023
Right to use	Non-current assets	16,822	16,822	39,473	40,823
Accumulated amortization	Non-current assets	(4,909)	(4,449)	(14,470)	(14,240)
Assets		11,912	12,372	25,003	26,583
Lease liabilities	Current liabilities	2,735	2,716	7,593	7,905
Adjustment to present value	Current liabilities	(929)	(959)	(2,139)	(2,259)
		1,806	1,757	5,454	5,646
Lease liabilities	Non-current liabilities	15,611	16,304	26,824	28,481
Adjustment to present value	Non-current liabilities	(2,734)	(2,954)	(4,386)	(4,832)
		12,877	13,350	22,438	23,649
Liabilities		14,683	15,107	27,892	29,295

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

16. Shareholders' equity

16.1. Capital

	Company and Consolidated	
	March 31, 2024	December 31, 2023
Subscribed and paid-up capital (in thousands of reais)	851,017	851,017
Number of common shares, without par value (number of shares)	552,495,663	552,495,663
Article 7 of Bylaws - authorization for the issuance of shares, without amendment to the Bylaws (number of shares)	80,000,000	80,000,000
Closing quotation: ODPV3 - B3 SA Brasil Bolsa Balcão (R\$/share)	12.16	11.62
Equity value (R\$/share)	2.79	2.92

16.2. Capital reserves

Other capital reserves: put option on subsidiaries and premium/discount on capital transaction, in the amount of (R\$ 35,610) ((R\$ 35,610) on December 31, 2023).

16.3. Profit reserves

	Company and Consolidated	
	March 31, 2024	December 31, 2023
Legal reserve	100,749	100,749
Statutory Reserve of Regulatory Capital	100,000	100,000
Investment and expansion statutory reserve	60,373	60,373
Tax incentive reserve	129	129
Additional dividend proposed	242,492	242,492
First investment reserve	57,936	57,936
	561,679	561,679

First investment reserve: refers to the values determined in the transition from CPC 50 / IFRS 17.

16.4. Other comprehensive income

	Company and Consolidated
Balance at December 31, 2022	(27,985)
Revenues and expenses recognized in the period in other comprehensive income	54,470
Deferred tax	(18,521)
Revenues and expenses recognized in the period in other comprehensive income of investees recognized under the equity method	735
Balance at December 31, 2023	8,699
Revenues and expenses recognized in the period in other comprehensive income	(7,023)
Deferred tax	2,387
Revenues and expenses recognized in the period in other comprehensive income of investees recognized under the equity method	(68)
Balance at March 31, 2024	3,995

16.5. Treasury shares

On a timely manner, the Company carries out Share Repurchase Programs which, in addition to regular payments of interest on own capital and dividends, have the objective of maximizing the generation of value for shareholders.

At a meeting on February 28, 2024, the Board of Directors approved a new Repurchase Program, the fourth since 2021, totaling 10 million shares, representing 3.9% of shares outstanding on the market, within a period of up to 18 months, ending on August 29, 2025.

Until March 31, 2024, the total number of Treasury shares acquired under the current Program reached 1,854,600 shares, with an average nominal cost of R\$ 11.96 per share, totaling R\$ 22,179.

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

16.6. Resolutions

Approval	Type	Date	Resolution		Company Competence	
			Dividend per share (R\$)	Payment date	2024	2023
RCA	Interest on own capital	03/14/2023	0.03844	12/19/2023	-	21,239
RCA	Interest on own capital	06/26/2023	0.03821	12/19/2023	-	21,110
RCA	Interest on own capital	09/19/2023	0.03718	12/19/2023	-	20,544
RCA	Interest on own capital	12/13/2023	0.03544	02/16/2024	-	19,580
RCA	Interest on own capital	03/27/2024	0.04137 ¹	08/21/2024	22,779	-
			Interest on own capital		22,779	82,473
AUG	Additional dividend proposed	02/28/2024	0.33633 ¹	08/21/2024	-	184,761
			Additional dividend to the minimum mandatory		-	184,761
AUG	Additional dividend proposed	02/28/2024	0.02774 ¹	08/21/2024	-	15,239
AUG	Additional dividend proposed	02/28/2024	0.41368 ¹	12/18/2024	-	227,253
			Additional dividend		-	242,492
			Total deliberated earnings		22,779	509,726

RCA = Board of Directors' Meeting.

AGO = Ordinary General Meeting

¹ The amount per share considers the treasury balance on the dividend position date.

17. Operating segments

The activities of the Company and its subsidiaries are organized in the following business segments:

- Corporate: includes clients over 200 beneficiaries;
- SMALL AND MEDIUM-SIZED ENTERPRISE (SME): clients sized between 3 and 199 beneficiaries;
- Individual: monthly and annual plans sold to individuals; and
- Other: segments with less representation in the Company's total revenues, as follows: (i) dental care service in the Company's dental clinics (Clidec and Boutique Dental); (ii) management and advisory services provided (Odontoprev Serviços and Oprev); (iii) acquisition and distribution of dental care materials for the accredited network (Dental Partner); (iv) software development (Easy); (v) health insurance (Odontored); and (vi) imaging diagnosis (Papaiz and Lúmax).

	Contribution margin - Consolidated									
	CORPORATE		SME		INDIVIDUAL		OTHER		TOTAL	
	Period ended March 31, 2024	Period ended March 31, 2023	Period ended March 31, 2024	Period ended March 31, 2023	Period ended March 31, 2024	Period ended March 31, 2023	Period ended March 31, 2024	Period ended March 31, 2023	Period ended March 31, 2024	Period ended March 31, 2023
Insurance revenue (Premium Allocation Approach—PAA)	291,637	272,111	118,097	113,139	-	-	13,146	3,066	422,880	388,316
Insurance revenue (Building Block Approach - BBA)	-	-	-	-	121,373	105,877	-	-	121,373	105,877
Insurance and reinsurance revenue	291,637	272,111	118,097	113,139	121,373	105,877	13,146	3,066	544,253	494,193
Sales of goods and services	-	-	-	-	-	-	13,871	11,056	13,871	11,056
Taxes on sales of goods and services	-	-	-	-	-	-	(3,623)	(4,356)	(3,623)	(4,356)
Revenue from sales of goods and services	-	-	-	-	-	-	10,248	6,700	10,248	6,700
SALES REVENUE	291,637	272,111	118,097	113,139	121,373	105,877	23,394	9,766	554,501	500,893
Events occurred	(160,723)	(136,039)	(7,007)	(6,758)	(18,389)	(14,792)	(9,293)	(4,767)	(195,412)	(162,356)
Costs of purchase	(21,625)	(19,657)	(13,593)	(12,747)	(21,764)	(32,832)	(1,662)	(207)	(58,644)	(65,443)
Tax expenses	(12,295)	(12,354)	(6,206)	(6,067)	(7,023)	(7,394)	-	-	(25,524)	(25,815)
OPERATING INCOME	96,994	104,061	91,291	87,567	74,197	50,859	12,439	4,792	274,921	247,279
CONTRIBUTION MARGIN	96,994	104,061	91,291	87,567	74,197	50,859	12,439	4,792	274,921	247,279
Sales revenue (%)	53.6	55.1	21.7	22.9	22.3	21.4	4.3	2.0	100.0	100.0
Margin x sales revenue (%)	33.3	38.2	77.3	77.4	61.1	48.0	53.2	49.1	49.6	49.4
Distribution of margin x total/segment (%)	35.3	42.1	33.2	35.4	27.0	20.6	4.5	1.9	100.0	100.0

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

18. Sales revenue

	Company		Consolidated	
	Period ended March 31,		Period ended March 31,	
	2024	2023	2024	2023
Considerations attributed to the PAA (Premium Allocation Approach) period	409,733	385,250	422,880	388,316
Revenues related to BBA (Building Block Approach) contracts	29,262	36,633	29,262	36,633
Change in the risk adjustment for non-financial risk	1,535	701	1,535	701
CSM recognized for services provided	69,391	37,051	69,391	37,051
Recovery of acquisition cash flow	21,185	31,492	21,185	31,492
Insurance and reinsurance revenue	531,106	491,127	544,253	494,193
Sale of goods and services	-	-	13,871	11,056
Taxes on sales of goods and services	-	-	(3,623)	(4,356)
	531,106	491,127	554,501	500,893

19. Insurance expenses

	Company		Consolidated	
	Period ended March 31,		Period ended March 31,	
	2024	2023	2024	2023
Events occurred	(184,712)	(157,188)	(195,412)	(162,356)
Costs of purchase	(56,673)	(64,930)	(58,644)	(65,443)
Tax expenses	(25,524)	(25,815)	(25,524)	(25,815)
Administrative expenses	(80,098)	(76,155)	(80,098)	(76,130)
	(347,007)	(324,088)	(359,678)	(329,744)

20. Financial income (loss)

	Company		Consolidated	
	Period ended March 31,		Period ended March 31,	
	2024	2023	2024	2023
Yields from financial investments	28,597	24,834	29,452	25,869
Inflation adjustment on judicial deposits	561	79	571	86
Inflation adjustment on tax credits ¹	3,449	476	3,449	484
Interest for late receipt ²	2,120	878	2,123	878
Other	651	53	651	146
Finance revenues	35,378	26,320	36,246	27,463
Bank fees	(1,236)	(1,061)	(1,257)	(1,113)
Adjustment to present value - lease liabilities (CPC 06 (R2)/IFRS 16)	(251)	(268)	(618)	(449)
Inflation adjustment of provision for judicial contingencies	(1,085)	(1,397)	(1,112)	(1,410)
Inflation adjustment - INSS return ³	-	9,465	-	9,465
Discounts granted	(236)	(366)	(236)	(366)
Interest accreditation (CPC 50 / IFRS 17)	(8,452)	(8,454)	(8,452)	(8,454)
Other financial expenses	(624)	(534)	(946)	(871)
Financial expenses	(11,884)	(2,615)	(12,621)	(3,198)
	23,494	23,705	23,625	24,265

¹ Update of Employer INSS credits, in which Odontoprev (which merged Rede Dental) received a final and unappealable decision in the lawsuit, securing its right to offset social security contributions unduly collected by Rede Dental on payments made to individual dentists between October 2007 to October 2019 (period after acquisition by Odontoprev).

² Refers mainly to the recognition of interest on individual/family plans.

³ Refers to amounts to be reimbursed to clients due to the success obtained in the National Social Security Institute – INSS lawsuit. In March 2023, the provision of the prescribed amounts was reversed.

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

21. Calculation of IRPJ/CSLL

	Company		Consolidated	
	Period ended March 31,		Period ended March 31,	
	2024	2023	2024	2023
Effect (CPC 50 / IFRS 17) before IRPJ and CSLL	(13,458)	(44,385)	(13,068)	(45,150)
IRPJ and CSLL calculation basis	221,666	242,950	223,941	246,235
	208,208	198,565	210,873	201,085
(x) Current rate (%)	34	34	34	34
Estimate of IRPJ and CSLL expenses, according to the current rate	(70,791)	(67,512)	(71,697)	(68,369)
Effect of Corporate Income Tax and Social contribution on permanent/temporary differences:				
Equity in net income of subsidiaries	1,754	2,290	434	569
Provision for lawsuits (Note 14.1)	(743)	616	(777)	336
Sundry provisions	910	1,285	915	1,240
Amortization of goodwill	487	3,024	487	3,024
Profit sharing	(1,874)	-	(2,153)	-
Interest on own capital	7,745	7,221	7,745	7,221
Adjustments - Law 12973/14	(13)	(48)	(12)	(52)
Other	(1,134)	(3,274)	(1,655)	(4,141)
Effect (CPC 50 / IFRS 17)	(4,575)	(15,091)	(4,443)	(15,351)
Current IRPJ and CSLL expense	(68,234)	(71,489)	(71,156)	(75,523)
Deferred IRPJ and CSLL revenue (expense)	1,953	(1,824)	2,552	(1,129)
Deferred IRPJ and CSLL revenue (CPC 50 / IFRS 17)	4,810	14,470	4,420	15,235
Total IRPJ and CSLL expense	(61,471)	(58,843)	(64,184)	(61,417)
Effective rate	29.5%	29.6%	30.4%	30.5%

22. Earnings per share – basic and diluted

	Period ended March 31,	
	2024	2023
Income attributable to Company's shareholders (in thousands of reais)	146,737	139,722
Weighted average number of common shares issued (thousands)	552,496	552,496
Basic and diluted earnings per share (R\$)	0.26559	0.25289

23. Related parties

Related party transactions are carried out at values, terms and average rates in line with the ones practiced with third parties (if any), in force on the respective dates.

Company's operations with its Subsidiaries and associated companies (Note 1)	Nature	March 31, 2024		December 31, 2023		March 31, 2024		March 31, 2023	
		Assets	Liabilities	Assets	Liabilities	Revenue	Expense	Revenue	Expense
Odontoprev	Administrative services	4,139	1,101	4,331	73	-	(14,111)	-	(19,828)
Odontoprev Serviços	Administrative services	1,125	-	735	-	12,959	-	18,575	-
Dental Partner	Administrative services	1,101	-	73	-	739	-	2,610	-
Brasidental	Administrative services	-	5,264	-	5,066	-	(3,605)	-	(3,155)
Odontoprev	Dental care plans	-	-	-	-	22	-	17	-
Odontoprev	Assumed/ceded co-responsibility	-	-	-	-	12,303	-	12,702	-
Brasidental	Assumed/ceded co-responsibility	-	-	-	-	-	(12,303)	-	(12,702)
Clidec	Dental materials and services	-	-	-	-	-	(12)	-	(4)
Clidec	Administrative services	-	-	-	-	6,796	-	5,896	-
Boutique Dental	Administrative services	-	-	-	-	1,055	-	1,294	-
Papaiz	Administrative services	-	-	-	-	1,316	-	893	-
Odontoprev	Dental services	-	-	-	-	-	(4,399)	-	(3,676)
Odontoprev	Dental materials	-	-	-	-	-	(739)	-	(2,487)
Clidec	Dental materials	-	-	-	-	-	-	-	(100)
Boutique Dental	Dental materials	-	-	-	-	-	-	-	(24)
Easy	Administrative services	-	-	-	-	-	(21)	-	(11)
Total		6,365	6,365	5,139	5,139	35,190	(35,190)	41,987	(41,987)

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

The Company and its Subsidiaries conduct transactions with companies of Bradesco Organization, of which Bradesco Saúde, shareholder of Odontoprev, is part:

Companies related to Banco Bradesco	Nature	March 31, 2024		December 31, 2023		March 31, 2024		Consolidated March 31, 2023	
		Assets	Liabilities	Assets	Liabilities	Revenue	Expense	Revenue	Expense
Alelo S.A.	Employee benefits	-	6	-	10	-	(1,345)	-	(1,491)
Banco Bradescard S.A.	Commissions	-	-	-	-	-	(39)	-	(1,275)
Banco Bradesco S.A.	Current account	640	-	1,069	-	-	-	-	-
Banco Bradesco S.A.	Interest earning bank deposit	1,157,889	-	967,959	-	28,479	-	24,240	-
Banco Bradesco S.A.	Revenue from services rendered	1	-	-	-	12,647	-	12,917	-
Banco Bradesco S.A.	Travel and accommodation - officers and employees	-	175	-	179	-	(355)	-	(525)
Banco Bradesco S.A.	Bookkeeping shares	-	-	-	-	-	(68)	-	(80)
Banco Bradesco S.A.	Rentals of branches	-	-	-	-	-	(74)	-	(72)
Banco Bradesco S.A.	Investment management	-	-	-	-	-	(100)	-	(83)
Banco Bradesco S.A.	Bank fee	-	-	-	-	-	(955)	-	(769)
Bradesco S/A Corretora De Títulos E Valores Mobiliários	Commission and brokerage fees	-	22,185	-	-	-	(6)	-	-
Bradesco Capitalização S.A.	Special savings bonds	4,996	-	4,353	-	-	-	-	-
Bradesco Saúde S.A.	Health care - Employees	-	-	-	-	-	(4,273)	-	(3,444)
Bradesco Saúde S.A.	Dividends and interest on own capital	-	238,022	-	108,076	-	-	-	-
Bradesco Vida e Previdência S.A.	Private pension - employees	-	119	-	119	-	(355)	-	-
Bradesco Vida e Previdência S.A.	Life insurance - Employees	-	6	-	6	-	(125)	-	(132)
Bradesco Corretora de Seguros Ltda.	Commissions	-	-	-	6	-	(35)	-	(14)
Bradseg Promotora de Vendas S.A.	Commissions	-	-	-	-	-	(8,714)	-	(4,455)
Braspag -Tecnologia em Pagamento Ltda.	Financial services	-	-	-	-	-	(152)	-	-
Brésia Empreendimentos E Participações Ltda.	Rentals of branches	-	-	-	-	-	(5)	-	(3)
Bsp Empreendimento Imobiliário D166 Ltda.	Rentals of branches	-	-	-	-	-	(15)	-	(17)
Bsp Park Estacionamento E Participações S.A.	Parking lot	-	-	-	-	-	(2)	-	(2)
Mediservice	Management fee	-	-	-	-	99	-	45	-
Reno Empreendimentos E Participações Ltda.	Rentals of branches	-	-	-	-	-	-	-	-
Santecorp Holding Ltda	Medical/outpatient services	-	-	-	-	-	(137)	-	(111)
Stelo S.A.	Management fee	-	-	-	-	-	-	-	(53)
Swiss Re Corporate Solutions Brasil Seguros S.A.	Legal guarantee insurance	-	-	-	-	-	(58)	-	(48)
		1,163,526	260,513	973,381	108,396	41,225	(16,813)	37,202	(12,574)

The Company contracted a court guarantee insurance related to the tax assessment notices on the stock options whose policies were contracted together with Swiss Re Corporate Solutions Brasil Seguros S.A. (Swiss Re Brasil) which has a joint venture with Bradesco Seguros S.A. (Bradesco Seguros).

The Company and its subsidiaries grant profit sharing to its employees and officers linked to the achievement of operating goals and specific objectives established and approved at the beginning of each year. As of March 31, 2024, the amounts of R\$ 5,510 (R\$ 5,586 as of March 31, 2023) and R\$ 6,620 (R\$ 6,659 as of March 31, 2023) were appropriated as profit sharing in the Company and in the Consolidated.

In 2019, the Company implemented a long-term incitement program (ILP Program), which establishes the criteria for the payment of cash bonuses, corresponding to salary multiples, to be made by the Company and its subsidiaries to the eligible beneficiaries after the measurement period, provided that the goals and conditions established in the terms are met. The stock options program remains in effect, as approved by the Shareholders' Meeting with the last granting being made in 2016.

The measurement period corresponds to three years and the payment is conditioned upon the achievement of the corporate performance targets established by the Board of Directors and the service condition.

As of March 31, 2024, R\$ 5,051 and R\$ 5,450 in the Company and Consolidated, respectively (R\$ 4,768 and R\$ 5,125 as of March 31, 2023) were appropriated to income (loss) for the period.

The annual fixed remuneration attributed to the Board of Directors and the Tax Council and the fixed/variable remuneration attributed to the Statutory Executive Board were as follows:

Odontoprev S.A.
Notes to the individual and consolidated, condensed interim financial statements
March 31, 2024 and 2023, and December 31, 2023
(Amounts expressed in thousands of Reais, unless otherwise indicated)

	Period ended March 31,	
	2024	2023
Statutory Board	1,848	1,755
Directors' fee	1,558	1,576
Benefits	205	179
Private pension	85	-
Board of Directors	960	960
Directors' fee	960	960
Fiscal Council	131	131
Directors' fee	131	131
	2,939	2,846

The Board of Directors and Tax Council, as well as the Personnel Management Committee, include members who are part of the management of Bradesco S.A. and Bradesco Seguros.

The Company does not sponsor post-employment benefit (except for a supplementary pension plan) or any termination of employment contract.

Other information the Company deems to be relevant

SHAREHOLDING POSITION OF THE HOLDERS OF OVER 5% OF THE COMPANY'S SHARES						
Position as of 03/31/2024						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Bradesco Saúde S.A.	292,213,236	52.89	-	-	292,213,236	52.89
1832 Asset Management L.P.	29,341,032	5.31	-	-	29,341,032	5.31
Treasury shares	1,854,600	0.34	-	-	1,854,600	0.34
Outstanding shares	229,086,795	41.46	-	-	229,086,795	41.46
Total	552,495,663	100.00	-	-	552,495,663	100.00

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Bradesco Saúde S.A.						
Position as of 03/31/2024						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Bradesco Gestão de Saúde S.A.	20,870,945	100.00	-	-	20,870,945	100.00

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Bradesco Gestão de Saúde S.A.						
Position as of 03/31/2024						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Bradseg Participações S.A.	12,251,025,598	100.00	-	-	12,251,025,598	100.00
Total	12,251,025,598	100.00	-	-	12,251,025,598	100.00

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Bradseg Participações S.A.						
Position as of 03/31/2024						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Banco Bradesco S.A.	12,318	100.00	-	-	12,318	100.00
Total	12,318	100.00	-	-	12,318	100.00

*according to the Reference Form of 04/02/2024, available on the RI website of Banco Bradesco.

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Banco Bradesco S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Cidade de Deus Companhia Comercial de Participações	2,445,219,983	45.87	1,292,135	0.02	2,446,512,118	22.99
Fundação Bradesco	914,471,634	17.16	3	0.00	914,471,637	8.59
NCF Participações S.A.	451,890,822	8.48	119,774,968	2.25	571,665,790	5.37
Other	1,506,751,642	28.27	5,180,209,241	97.53	6,686,960,883	62.83
Treasury shares	11,970,600	0.22	10,589,200	0.20	22,559,800	0.21
Total	5,330,304,681	100.00	5,311,865,547	100.00	10,642,170,228	100.00

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Cidade de Deus Companhia Comercial de Participações						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Fundação Bradesco	2,779,096,924	35.44	-	-	2,779,096,924	35.44
Nova Cidade de Deus Participações S.A.	3,758,724,093	47.93	-	-	3,758,724,093	47.93
Other	1,304,138,507	16.63	-	-	1,304,138,507	16.63
Total	7,841,959,524	100.00	-	-	7,841,959,524	100.00

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: NCF Participações S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Cidade de Deus Companhia Comercial de Participações	1,367,843,225	74.72	-	-	1,367,843,225	39.51
Fundação Bradesco	460,004,645	25.13	1,631,492,454	100.00	2,091,497,099	60.41
Nova Cidade de Deus Participações S.A.	2,738,642	0.15	-	-	2,738,642	0.08
Total	1,830,586,512	100.00	1,631,492,454	100.00	3,462,078,966	100.00

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Nova Cidade de Deus Participações S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
BBD Participações S.A.	189,425,112	53.70	-	-	189,425,112	26.07
Fundação Bradesco	163,332,621	46.30	373,794,914	100.00	537,127,535	73.93
Total	352,757,733	100.00	373,794,914	100.00	726,552,647	100.00

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: BBD Participações S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Treasury shares	45,919,796	20.71	18,727,526	8.45	64,647,322	14.58
NCD Participações Ltda	67,114,094	30.27	141,898,399	64.05	209,012,493	47.15
Other	108,710,981	49.03	60,934,301	27.50	169,645,282	38.27
Total	221,744,871	100.00	221,560,226	100.00	443,305,097	100.00


BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: NCD Participações Ltda						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Fundação Bradesco	793,303,109	1.00	-	-	773,303,109	1.00
Other	1	0.00	-	-	1	0.00
Total	793,303,110	1.00	-	-	773,303,110	1.00

Other information the Company deems to be relevant

CONSOLIDATED SHAREHOLDING POSITION OF THE CONTROLLING SHAREHOLDERS AND DIRECTORS AND OFFICERS AND SHARES IN CIRCULATION						
Position as of 03/31/2024						
Shareholder	Number of common shares (in units)	%	Number of preferred shares (in units)	%	Total number of Shares (in units)	%
Controlling managers	292,213,236	52.89	-	-	292,213,236	52.89
Managers	1,390,659	0.25	-	-	1,390,659	0.25
Treasury shares	1,854,600	0.34	-	-	1,854,600	0.34
Other	257,037,168	46.52	-	-	257,037,168	46.52
Total	-	100.00	-	-	552,495,663	100.00
Outstanding shares	-	46.52	-	-	257,037,168	46.52

CONSOLIDATED SHAREHOLDING POSITION OF THE CONTROLLING SHAREHOLDERS AND DIRECTORS AND OFFICERS AND SHARES IN CIRCULATION						
Position as of 03/31/2023						
Shareholder	Number of common shares (in units)	%	Number of preferred shares (in units)	%	Total number of Shares (in units)	%
Controlling managers	292,213,236	51.40	-	-	292,213,236	51.40
Managers	1,425,795	0.25	-	-	1,425,795	0.25
Treasury shares	15,970,140	2.81	-	-	15,970,140	2.81
Other	258,856,632	45.54	-	-	258,856,632	45.54
Total	568,465,803	100.00	-	-	568,465,803	100.00
Outstanding shares	258,856,632	45.54	-	-	258,856,632	45.53

Other information the Company deems to be relevant



Opinions and Statements / Special Review Report - Unqualified

To The Board of Directors and Shareholders of
Odontoprev S.A.
Barueri - SP

Introduction

We have reviewed the interim, individual and consolidated, condensed financial information of Odontoprev S.A. ("Company"), contained in the Quarterly Information - ITR Form for the quarter ended March 31, 2024, which comprise the balance sheet on March 31, 2024 and related statements of income, of comprehensive income, of changes in shareholders' equity and of cash flows for the quarter then ended, including explanatory notes.

Company's Management is responsible for the preparation of the individual interim financial information in accordance with CPC 21(R1) and the consolidated, condensed interim financial information in accordance with CPC 21 (R1) and with international standard IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board - (IASB), as well as for the presentation of this information in a manner consistent with the standards issued by the Brazilian Securities and Exchange Commission, applicable to the preparation of the Quarterly Information (ITR). Our responsibility is to express a conclusion on these interim financial information based on our review.

Scope of the review

Our review was carried out in accordance with the Brazilian and international review standards for interim information (NBC TR 2410 – Review of Interim Financial Information Performed by the Independent Auditor of the Entity and ISRE 2410 – Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim information consists in asking questions, chiefly to the persons in charge of financial and accounting affairs, and in applying analytical procedures and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Brazilian and International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion on the individual interim information

Based on our review, we are not aware of any facts that would lead us to believe that the interim, individual condensed financial information included in the quarterly information referred to above was not prepared, in all material respects, in accordance with CPC 21(R1) applicable to the preparation of Quarterly Information (ITR), and presented in a manner consistent with the standards issued by the Securities Commission.

Conclusion on the consolidated interim information

Based on our review, we are not aware of any facts that would lead us to believe that the interim consolidated, condensed financial information included in the quarterly information referred to above was not prepared, in all material respects, in accordance with CPC 21 (R1) and IAS 34, applicable to the preparation of Quarterly Information - ITR, and presented in a manner consistent with the standards issued by the Securities Commission.

Other issues - Statements of added value

The aforementioned quarterly information includes the individual and consolidated statements of added value for the three-month period ended March 31, 2024, prepared under responsibility of Company's Management, and presented as supplementary information for IAS 34 purposes. These statements have been subject to review procedures performed in conjunction with the review of the quarterly information, in order to determine whether they are reconciled with the interim financial information and book records, as applicable, and whether their form and content are in accordance with the criteria defined in Technical Pronouncement CPC 09 – Statement of Added Value. Based on our review, we are not aware of any facts that may lead us to believe that those statements of added value have not been prepared, in all material respects, in accordance with the criteria set forth in this Standard and consistently with respect to the individual and consolidated interim financial information taken as a whole.

São Paulo, May 07, 2024

KPMG Auditores Independentes Ltda.
CRC 2SP-027685/O-0 F SP

Cláudio Rogélio Sertório - Accountant
CRC 1SP212059/O-0

Opinions and Statements / Statement of the Executive Officers on the Financial Statements

We declare, in our capacity as Statutory Directors of Odontoprev S.A., a joint stock company headquartered in the city of Barueri, state of São Paulo, at Alameda Araguaia, 2104, 21º Andar - Alphaville, CNPJ [EIN] 58.119.199/0001-51, pursuant to article 27, §1, item VI of CVM Resolution 80 of March 29, 2022, as amended, which we reviewed, discussed and agreed with the Financial Statements for the first quarter of 2024.

Barueri/SP, May 07, 2024

Opinions and Statements / Statement of the Directors on Independent Auditor's Report

We declare, in our capacity as Statutory Directors of Odontoprev S.A., a joint stock company headquartered in the city of Barueri, state of São Paulo, at Alameda Araguaia, 2104, 21º Andar - Alphaville, CNPJ [EIN] 58.119.199/0001-51, pursuant to article 27, §1, item V of CVM Resolution 80 of March 29, 2022, as amended, which we reviewed, discussed and agreed with the opinions expressed in the report of the independent auditors of the Company, KPMG Auditores Independentes Ltda., referring to the Company's 1Q24 quarterly earnings.

Barueri/SP, May 07, 2024